

***** Welcome to STN International *****
 ***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:34:51 ON 24 JAN 2006

=> file reg

=>Uploading C:\Program Files\Stnexp\Queries\10699563a.str

L6 STRUCTURE UPLOADED

=> s 16 sam

L7 20 SEA SSS SAM L6

=> s 16 full

L8 404 SEA SSS FUL L6

=> file caplus

=> s 18

L9 32 L8

=> s 19 and pd< march 2001

21572372 PD< MARCH 2001

(PD<20010300)

L10 17 L9 AND PD< MARCH 2001

=> s 19 not l10

L11 15 L9 NOT L10

=> dis l11 1-15 bib abs

L11 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1289898 CAPLUS

DN 144:36334

TI Preparation of phenyl benzoyl pyrazoles as CRTH2 receptor ligands

IN Ulven, Trond; Frimurer, Thomas; Rist, Oeystein; Kostenis, Evi; Hoegberg, Thomas; Receveur, Jean-Marie; Grimstrup, Marie

PA 7TM Pharma A/S, Den.

SO PCT Int. Appl., 115 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005115382	A1	20051208	WO 2005-EP5884	20050530
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI GB 2004-12198 A 20040529
 GB 2004-14196 A 20040624
 GB 2004-24018 A 20041029
 GI



AB Title compds. I [A = carboxy, carboxy bioisostere; A1 = H, Me; Ar1 = (un)substituted heteroaryl in which the groups OCHAA1 and L2 are linked to adjacent ring atoms; Ar2-3 = heteroaryl; n = 0-1; L2-3 = divalent radical (Alk1)m-Zq-(Alk2)p; m, q, p = 0-1; Alk1-2 = alkylene which may be heteroatom substituted, etc.; Z = O, S, CO SO2, etc.; with some provisions] are prepared For instance, 4-bromo-2-((1-phenyl-1H-pyrazole-4-yl)carbonyl)phenoxyacetic acid (II) is prepared in 2 steps from (5-bromo-2-hydroxyphenyl)(1-phenyl-1H-pyrazol-4-yl)methanone and Et bromoacetate. II has an IC50 < 0.5 µM for the CRTH2 receptor. I are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:588670 CAPLUS

DN 143:91048

TI Treatment of reflux-related diseases with oxazole or oxadiazole compounds inhibiting transient lower esophageal sphincter relaxations

IN Lehmann, Anders; Mattsson, Jan

PA Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060971	A1	20050707	WO 2004-US41132	20041210
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2003-530691P P 20031218

OS MARPAT 143:91048

AB The present invention relates to the use of certain compds. for the

inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of certain compds. for the treatment of gastro-esophageal reflux disease, regurgitation, asthma, laryngitis, lung disease and for managing failure to thrive. The compds. have the formula Ar1-L-Ar2 (Ar1 = (substituted) heterocycle; Ar2 = (substituted) carbocycle; L has 1-14 atoms) or a pharmaceutically acceptable salt or an optical isomer.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:588662 CAPLUS
DN 143:71789
TI Novel treatment of irritable bowel syndrome I
IN Lindstroem, Erik; Larsson, Hakan; Lehmann, Anders
PA Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060965	A1	20050707	WO 2004-US41005	20041208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


PRAI SE 2003-3418 A 20031217
AB The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment of antagonists (IBS).
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:588659 CAPLUS
DN 143:91047
TI Novel treatment of gerd
IN Lehmann, Anders; Mattsson, Jan
PA Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060961	A2	20050707	WO 2004-US41133	20041210
WO 2005060961	A3	20050707		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-530232P P 20031218
 OS MARPAT 143:91047
 GI



AB The present invention relates to the use of a compound of formula I (where X,Y,and Z are independently selected from the group consisting of N,O,S,C,and CO wherein at least one of X,Y,and Z is a heteroatom ;Ar1 and Ar2 are independently selected from the group consisting of a heterocyclic or fused heterocyclic moiety, etc.) for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of compds. of formula (II) for the treatment of gastro-esophageal reflux disease.

L11 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:470256 CAPLUS

DN 143:20052

TI Urea derivatives as kinase modulators

IN Milanov, Zdravko V.; Patel, Hitesh K.; Grotzfeld, Robert M.; Mehta, Shamal A.; Andiliy, Lai G.; Lockhart, David J.

PA Ambit Biosciences Corporation, USA

SO PCT Int. Appl., 350 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005048948	A2	20050602	WO 2004-US38288	20041115
	WO 2005048948	A3	20050728		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005148605	A1	20050707	US 2004-989745	20041115

US 2005165031	A1	20050728	US 2004-989814	20041115
US 2005165024	A1	20050728	US 2004-989824	20041115
US 2005165074	A1	20050728	US 2004-990007	20041115
US 2005171171	A1	20050804	US 2004-989766	20041115
US 2005171172	A1	20050804	US 2004-989823	20041115
US 2005192314	A1	20050901	US 2004-990195	20041115
US 2005197371	A1	20050908	US 2004-990194	20041115
US 2005261315	A1	20051124	US 2004-989623	20041115
US 2005267182	A1	20051201	US 2004-989717	20041115
PRAI US 2003-520273P	P	20031113		
US 2003-527094P	P	20031203		
US 2003-531082P	P	20031218		
US 2003-531243P	P	20031218		
OS MARPAT 143:20052				
AB	The invention provides methods and compns. for treating conditions mediated by various kinases wherein derivs. of urea compds. are employed. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects such as cellular proliferative disorders.			

L11 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:409481 CAPLUS

DN 142:463620

TI Preparation of N-(oxoazepanyl) benzenesulfonamides and related derivatives as γ -secretase inhibitors for treating Alzheimer's disease

IN Neitzel, Martin; Dappen, Michael S.; Marugg, Jennifer

PA Elan Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 205 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2005042489	A1	20050512	WO 2004-US35951	20041029
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005165003	A1	20050728	US 2004-976746	20041029
PRAI	US 2003-515612P	P	20031029		
OS	MARPAT 142:463620				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein A = (CH₂)_n; n = 1-3; R₁ = (un)substituted arylalk(en/yn)yl, alk(en/yn)yl, heteroarylalkyl, etc.; R₂ = H,

phenyl/alkyl; R3 = H, halo, halo/alkyl, alkoxy, CN; R4 = H, halo, (un)substituted alkyl; or R3CCR4 = (un)substituted heterocycloalkyl; R3' = H, halo, SO₂NH₂ and derivs.; or R3'CCR4 = benzo ring, 1-oxa-2,3-diazacyclopentyl; R6, R5 = independently H, F; R6CCR3 = 1,2,5-oxadiazolyl, naphthyl; and their pharmaceutically acceptable salts] were prepared as selective γ -secretase inhibitors for treating or preventing cognitive disorders, such as Alzheimer's disease. About 700 tabulated examples and 3 general synthetic procedures are given. Selected I, e.g. II, inhibited γ -secretase with IC₅₀ within the range of from about 0.1-25 nM.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1124567 CAPLUS
DN 142:74572
TI Preparation of heterocyclic compounds for treating hepatitis C virus
IN Vourloumis, Dionisios; Takahashi, Masayuki; Winters, Geoff; Zhou, Jinglan; Duchene, Russell
PA Anadys Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110351	A2	20041223	WO 2004-US15249	20040514
	WO 2004110351	A3	20050428		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005075375	A1	20050407	US 2004-845587	20040514
PRAI	US 2003-470200P	P	20030514		
OS	MARPAT 142:74572				
GI					



AB The title compds. I [X, Y, Z = C, N; W = N, O, S; R1, R3-R5 = H, halo, NO2, etc.; R2 = H, alkyl], useful for treating Hepatitis C virus, were prepared E.g., a multi-step synthesis of II, starting from 2'-hydroxy-5'-methoxyacetophenone, was given. The compds. I were tested for inhibition of HCV replication in in vitro assays (the results of EC50 assay are given for 640 compds. I). The pharmaceutical composition comprising the compound I is disclosed.

L11 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:654838 CAPLUS

DN 141:325154

TI Discovery of Novel Heteroarylazoles That Are Metabotropic Glutamate Subtype 5 Receptor Antagonists with Anxiolytic Activity

AU Roppe, Jeffrey; Smith, Nicholas D.; Huang, Dehua; Tehrani, Lida; Wang, Bowei; Anderson, Jeffrey; Brodtkin, Jesse; Chung, Janice; Jiang, Xiaohui; King, Christopher; Munoz, Benito; Varney, Mark A.; Prasit, Petpiboon; Cosford, Nicholas D. P.

CS Merck Research Laboratories, San Diego, CA, 92121, USA

SO Journal of Medicinal Chemistry (2004), 47(19), 4645-4648

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 141:325154

AB The highly potent, selective, and brain-penetrant metabotropic glutamate subtype 5 (mGlu5) receptor antagonists 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile and 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile are reported. Compound 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile is active in the rat fear-potentiated startle (FPS) model of anxiety with ED50 = 5.4 mg/kg (po) when dosed acutely. In this model the anxiolytic effects of 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile rapidly tolerate on repeated dosing.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:353142 CAPLUS

DN 140:357200

TI Preparation of sulfonamidomethyl and carboxamidomethyl phosphonate inhibitors of β -lactamase

IN Besterman, Jeffrey M.; Rahil, Jubrail; Vaisburg, Arkadii

PA Methylgene, Inc., Can.

SO U.S. Pat. Appl. Publ., 134 pp., Cont.-in-part of U.S. Pat. Appl. 2004

29,836.


CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004082546	A1	20040429	US 2003-411484	20030408
	US 6921756	B2	20050726		
	US 6472406	B1	20021029	US 2000-610456	20000705
	US 2004059115	A1	20040325	US 2002-266213	20021008
	US 2004029836	A1	20040212	US 2002-302124	20021122
	US 6884791	B2	20050426		
	WO 2004048393	A2	20040610	WO 2003-US36929	20031119
	WO 2004048393	A3	20040819		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-142362P	P	19990706		
	US 2000-610456	A2	20000705		
	US 2002-266213	A2	20021008		
	US 2002-302124	A2	20021122		
	US 2003-411484	A1	20030408		
OS	MARPAT 140:357200				
GI					




AB The invention relates to bacterial antibiotic resistance and, in particular, to compns. and methods for overcoming bacterial antibiotic resistance. The invention provides novel β -lactamase inhibitors I [R1 = (un)substituted (hetero)aryl; Z = C, CH₂, S; n = 0-2; L = alkyl, alkoxy, CO, C(:NOMe); R2 = H, alkyl, cycloalkyl, aralkyl, aryl; R3 = H, alkyl, cycloalkyl, aryl, etc.; R4 = OH, F, SR7, N(R7)₂; R5 = F, OR6, SR7, N(R7)₂; R6 = H, alkyl, cycloalkyl, etc.; R7 = H, alkyl, cycloalkyl, etc.; with the provisos] which are structurally unrelated to the natural product and semi-synthetic β -lactamase inhibitors presently available and which do not require a β -lactam pharmacophore. The invention also

provides pharmaceutical compns. and methods for inhibiting bacterial growth. Preparation of compds. I is described. E.g., a 4-step synthesis of sodium salt of II which showed IC50 of 622 μ M against β -lactamase, was given.

L11 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:120574 CAPLUS
 DN 140:181318
 TI Preparation of sulfonamidomethyl and carboxamidomethyl phosphonate inhibitors of β -lactamase
 IN Besterman, Jeffrey M.; Rahil, Jubrail; Vaisburg, Arkadii
 PA Methylgene, Inc., Can.
 SO U.S. Pat. Appl. Publ., 96 pp., Cont.-in-part of U.S. Ser. No. 266,213. CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004029836	A1	20040212	US 2002-302124	20021122
	US 6884791	B2	20050426		
	US 6472406	B1	20021029	US 2000-610456	20000705
	US 2004059115	A1	20040325	US 2002-266213	20021008
	US 2004082546	A1	20040429	US 2003-411484	20030408
	US 6921756	B2	20050726		
	WO 2004048393	A2	20040610	WO 2003-US36929	20031119
	WO 2004048393	A3	20040819		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005043276	A1	20050224	US 2004-884435	20040702
PRAI	US 1999-142362P	P	19990706		
	US 2000-610456	A2	20000705		
	US 2002-266213	A2	20021008		
	US 2002-302124	A2	20021122		
	US 2003-411484	A1	20030408		
OS	MARPAT 140:181318				
GI					



AB The invention relates to bacterial antibiotic resistance and, in particular, to compns. and methods for overcoming bacterial antibiotic resistance. The invention provides novel β -lactamase inhibitors I [R1 = (un)substituted (hetero)aryl; Z = C, CH₂, S; n = 0-2 when Z = S; n = 1 when Z = C; n = 0 when Z = CH₂; L = alkyl, alkoxy, CO, C(:NOMe); R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, aryl, etc.; R4 = OH, F, SR7, N(R7)₂; R5 = F, OR6, SR7, N(R7)₂; R6 = H, alkyl, cycloalkyl, etc.; R7 = H, alkyl, cycloalkyl, etc.; with the provisos] which are structurally unrelated to the natural product and semi-synthetic β -lactamase inhibitors presently available and which do not require a β -lactam pharmacophore. The invention also provides pharmaceutical compns. and methods for inhibiting bacterial growth. Preparation of compds. I is described. E.g., a 4-step synthesis of sodium salt of II which showed IC₅₀ of 622 μ M against β -lactamase, was given.

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:2699 CAPLUS

DN 140:53471

TI Use of metabotropic glutamate receptor 5 (MGLUR5) antagonists for the treatment of gastroesophageal reflux disease (GERD) and other conditions

IN Lehmann, Anders; Mattsson, Jan

PA Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000316	A1	20031231	WO 2003-US16223	20030619
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2489730	AA	20031231	CA 2003-2489730	20030619
	BR 2003011759	A	20050308	BR 2003-11759	20030619
	EP 1513525	A1	20050316	EP 2003-731333	20030619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	NO 2005000154	A	20050111	NO 2005-154	20050111
PRAI	SE 2002-1943	A	20020620		
	WO 2003-US16223	W	20030619		



AB The invention discloses the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. The invention also discloses the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation, asthma, chronic laryngitis, lung disease, and failure to thrive.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:875115 CAPLUS
 DN 139:364949
 TI Preparation of triaryl-oxy-aryloxy-pyrimidinetrione metalloproteinase
 inhibitors with selectivity towards MMP-13
 IN Reiter, Lawrence Alan; Freeman-Cook, Kevin Daniel
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 100 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION-NO.	DATE
PI	WO 2003090752	A1	20031106	WO 2003-IB1560	20030415
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2484067	AA	20031106	CA 2003-2484067	20030415
	EP 1501515	A1	20050202	EP 2003-712588	20030415
	EP 1501515	B1	20051102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009386	A	20050222	BR 2003-9386	20030415
	JP 2005529132	T2	20050929	JP 2003-587386	20030415
	AT 308325	E	20051115	AT 2003-712588	20030415
	US 2004006057	A1	20040108	US 2003-424614	20030428
PRAI	US 2002-375990P	P	20020426		
	WO 2003-IB1560	W	20030415		
OS	MARPAT 139:364949				
GI					



AB The present invention relates to triaryl-oxy-aryloxy-pyrimidine-2,4,6-triones (shown as I; variables defined below; e.g. II) that are metalloproteinase inhibitors and to pharmaceutical compns. and methods of treating inflammation, cancer and other disorders. For I: R1 = H, (R2)2n+1Cn- and (C3-C7)cycloalkyl; n = 1-5; each R2 = halo, (C1-C4)alkenyl, (C1-C4)alkynyl, R3-, R3O-, perfluoro(C1-C4)alkoxy, R3C(O)O-, (R3)2NC(O)O-, -NO2, (R3)2N-, R3SO2NR4-, (R3)2NC(O)-, R3C(O)(NR4)-, R3OC(O)(NR4)-, (R3)2NC(O)NR4-, R3S-, R3S(O)-, R3SO2-, (R3)2NSO2-, -CN, R3OC(O)-, and R3C(O). X = -O-, >C:O, -S-, >SO2, >S:O, >NR5, -CH2-, -CH2O-, -OCH2-, -CH2S-, -CH2S(O)-, -CH2SO2-, -SCH2-, -S(O)CH2-, -SO2CH2-, -[N(R5)]CH2-, -CH2[N(R5)]-, -[N(R5)]SO2- and -SO2[N(R5)]-; A = (C6-C10)aryl or (C1-C10)heteroaryl; Y = a bond, -O-, -S-, >C:O, >SO2, >S:O, -CH2O-, -OCH2-, -CH2S-, -SCH2-, -CH2SO-, -CH2SO2-, -SOCH2-, -SO2CH2-, >NR6, -[N(R6)]CH2-, -CH2[N(R6)]-, -CH2-, -CH:CH-, -C:C-, -[N(R6)]SO2- and -SO2[N(R6)]-; B = (C6-C10)aryl, (C3-C7)cycloalkyl, (C1-C10)heterocyclyl and (C1-C10)heteroaryl. G = -[R7(CR8R9)p]-; wherein the orientation of -B-G-W is -B-[R7-(CR8R9)p]-W or -B-[(CR8R9)p-R7]-W; p = 0-4; W = (C1-C4)alkoxy(C1-C4)alkyl, (C3-C7)cycloalkyl, (C6-C10)aryl, (C1-C10)heteroaryl and (C1-C10)heterocyclyl; addnl. details including provisos are given in the claims. General semiquant. statements are made about inhibition of metalloproteinases by I; no data is presented for specific examples of I. Although the methods of preparation are not claimed, example preps. of 8 intermediates and 76 I are included.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:676015 CAPLUS

DN 137:201315

TI Heteropolycyclic compounds, particularly pyridyl- and phenyl-substituted 1,2,4-oxadiazoles and analogs, and their use as metabotropic glutamate receptor antagonists for inhibiting neuronal damage

IN Slassi, Abdelmalik; Van Wagenen, Bradford; Stormann, Thomas M.; Moe, Scott T.; Sheehan, Susan M.; McLeod, Donald A.; Smith, Daryl L.; Isaac, Methvin Benjamin

PA Can.

SO PCT Int. Appl., 272 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002068417	A2	20020906	WO 2002-US4689	20020219
	WO 2002068417	A3	20021114		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2438991	AA	20020906	CA 2002-2438991	20020219
	EP 1379525	A2	20040114	EP 2002-787093	20020219
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2002007390	A	20041013	BR 2002-7390	20020219
	JP 2004536037	T2	20041202	JP 2002-567930	20020219
	NO 2003003711	A	20031017	NO 2003-3711	20030820
	ZA 2003006493	A	20041122	ZA 2003-6493	20030820
PRAI	US 2001-269847P	P	20010221		
	WO 2002-US4689	W	20020219		
OS	MARPAT 137:201315				
GI					



AB The invention provides compds. and pharmaceutical compns. that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurol. diseases and disorders. Methods of preparing the compds. also are disclosed. The compds. exhibit a high degree of potency and selectivity for individual metabotropic glutamate receptor subtypes, notably mGluR5. In particular, medical conditions associated with metabotropic glutamate receptors and therefore targeted by the invention compds. include stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, and Alzheimer's disease. The invention provides methods of treating diseases associated with excitatory activation of an mGluR Group I receptor, and of inhibiting neuronal damage caused by excitatory activation of an mGluR Group I receptor, specifically wherein the mGluR Group I receptor is mGluR5. In one aspect of the invention, the antagonists may be represented by the general formula Ar1-L-Ar2, wherein Ar1 is an optionally substituted heteroarom. moiety, and Ar2 is an optionally substituted benzene ring. The L moiety is a group that not only covalently binds to the Ar1 and Ar2 moieties, and which facilitates adoption of the correct spatial orientation of Ar1 and Ar2, but also itself may interact with the protein, to effect receptor

binding. In one embodiment of the invention, L is selected from the group consisting of -NH-, -S-, -O-, -CO-, -CONH-, -CONHCH₂-, -CH₂CONH-, -CNHNH-, -CNHNHCH₂-, -C=NOCH₂-, -CH₂NHCH₂-, -CH₂CH₂NH-, -NHCH₂CO-, -NHCH₂CHOH-, -NHCNHNH-, -NHCONH-, cyclopentane, cyclopentadiene, furan, thiofuran, pyrrolidine, pyrrole, 2-imidazoline, 3-imidazoline, 4-imidazoline, imidazole, pyrazoline, pyrazolidine, imidazolidine, oxazole, 2-oxazole, thiazole, isoxazole, isothiazole, 1H-1,2,4-triazole, 1H-1,2,3-triazole, 1,2,4-oxathiazole, 1,3,4-oxathiazole, 1,4,2-dioxazole, 1,4,2-oxathiazole, 1,2,4-oxadiazole, 1,2,4-thiadiazole, 1,2,5-oxadiazole, 1,2,5-thiadiazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1H-tetrazole, cyclohexane, piperidine, tetrahydropyridine, 1,4-dihydropyridine, pyridine, benzene, tetrahydropyran, 3,4-dihydro-2H-pyran, 2H-pyran, 4H-pyran, tetrahydrothiopyran, 3,4-dihydro-2H-thiopyran, 2H-thiin, 4H-thiopyran, morpholine, thiomorpholine, piperazine, pyridazine, pyrimidine, pyrazine, 1,2,4-triazine, 1,2,3-triazine, 1,3,5-triazine, and 1,2,4,5-tetrazine. In another embodiment of the invention, Ar₁ is selected from the group consisting of Ph, benzyl, naphthyl, fluorenyl, anthrenyl, indenyl, phenanthrenyl, and benzonaphthenyl, and Ar₂ is selected from the group consisting of thiazoyl, furyl, pyranyl, 2H-pyrrolyl, thienyl, pyrrolyl, imidazoyl, pyrazoyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzothiazole, benzimidazole, 3H-indolyl, indolyl, indazoyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalizinyl, naphthyridinyl, quinazolinyl, cinnolinyl, isothiazolyl, quinoxalinyl, indolizinyl, isoindolyl, benzothienyl, benzofuranyl, isobenzofuranyl, and chromenyl. Several hundred specific examples are individually prepared and/or claimed. A variety of intermediates were also prepared. For instance, 5-methylpyrid-2-ylamidoxime was prepared from 2-bromo-5-methylpyridine by Zn- and Pd-complex-mediated cyanation (56%) and reaction of the resulting nitrile with NH₂OH.HCl (60%). Cyclization of the amidoxime with 3-cyanobenzoyl chloride (86%) gave invention compound I. In a bioassay for mGluR5 antagonism in primary astrocyte cultures from rats, the invention compds. had IC₅₀ values in the range of 11 to 9140 nM.

L11 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:632134 CAPLUS

DN 137:286807

TI Influence of chemical structure on the mesomorphic behaviour of 3,5-disubstituted 1,2,4-oxadiazoles

AU Torgova, S.; Karamysheva, L.; Strigazzi, A.

CS FSUE"SRC"NIOPIK" (Organic Intermediates & Dyes Institute), Moscow, 103787, Russia

SO Brazilian Journal of Physics (2002), 32(2B), 593-601

CODEN: BJPHE6; ISSN: 0103-9733

PB Sociedade Brasileira de Fisica

DT Journal

LA English

AB The correlation between chemical structure and mesomorphic properties is one of the most important problems in liquid crystal science. 3,5-Disubstituted 1,2,4-oxadiazoles are very convenient model-compds. for studying the dependence of the LC properties on the mol. design. The transition temps. and dielec. properties of 1,2,4-oxadiazoles depend significantly both on the position of the substituents with respect to the heterocycle and on their donor or acceptor features.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN


AN 2002:593318 CAPLUS

DN 137:270916
 TI Dielectric, calorimetric and optical investigations of pyridine-containing oxadiazoles
 AU Becchi, Marta; Agafonova, Irina F.; Geivandova, Tatiana A.; Karamysheva, Ludmila A.; Torgova, Sofia I.; Umanskii, Boris A.; Strigazzi, Alfredo
 CS Dipartimento di Fisica, Politecnico di Torino, Turin, I-10129, Italy
 SO Molecular Crystals and Liquid Crystals Science and Technology, Section A: Molecular Crystals and Liquid Crystals (2002), Volume Date 2001, 372, 189-199
 CODEN: MCLCE9; ISSN: 1058-725X
 PB Taylor & Francis Ltd.
 DT Journal
 LA English
 AB Three series of new isomeric 4-, 3- and 2-pyridine containing 1,2,4-oxadiazoles were studied via DSC and optical microscopy. DSC and microscopy studies are mostly in good agreement and show that the transition temps. and type of mesophases strictly depend on the nature and the length of the substituent in the oxazolic part of 1,2,4-oxadiazoles and on the position of the heteroatom in the pyridine substituent. The mesomorphic properties of the compds. under study were compared with analogous 1,2,4-oxadiazoles, containing only carbocyclic units.
 RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis l11 15 hitstr


L11 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
 IT **387400-51-3 387400-52-4**
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
 (liquid crystal properties and phase transition enthalpy of)
 RN 387400-51-3 CAPLUS
 CN Pyridine, 2-[5-[4-(trans-4-propylcyclohexyl)phenyl]-1,2,4-oxadiazol-3-yl]-
 (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 387400-52-4 CAPLUS
 CN Pyridine, 2-[5-[4-(trans-4-pentylcyclohexyl)phenyl]-1,2,4-oxadiazol-3-yl]-
 (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> dis 110 1-17 bib abs hitstr

L10 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:222333 CAPLUS

DN 138:255233

TI Heteropolycyclic compounds, particularly pyridyl- and phenyl-substituted 1,2,4-oxadiazoles and analogs, and their use as metabotropic glutamate receptor antagonists for inhibiting neuronal damage

IN Van Wagenen, Bradford; Stormann, Thomas M.; Moe, Scott T.; Sheehan, Susan M.; McLeod, Donald A.; Smith, Daryl L.; Isaac, Methvin Benjamin; Slassi, Abdelmalik

PA NPS Pharmaceuticals, Inc., USA


SO U.S. Pat. Appl. Publ., 151 pp., Cont.-in-part of Appl. No. PCT/US00/22618. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003055085	A1	20030320	US 2002-76618	20020219
	US 6660753	B2	20031209		
	WO 2001012627	A1	20010222	WO 2000-US22618	20000818 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1582519	A2	20051005	EP 2005-14788	20000818
	EP 1582519	A3	20051221		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 2005154027	A1	20050714	US 2003-699563	20031103
PRAI	US 1999-149464P	P	19990819		
	WO 2000-US22618	A2	20000818		
	US 2001-269847P	P	20010221		
	EP 2000-955657	A3	20000818		
	US 2002-76618	A1	20020219		
OS	MARPAT 138:255233				
GI					



AB The title compds. [I; X, Y, Z = N, O, S, CR1 and at least one of X, Y, and Z = heteroatom; R1 = H, alkyl, CF₃, etc.; Ar1, Ar2 = (un)substituted (hetero)aryl] that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurol. diseases and disorders, were prepared. The compds. I exhibit a high degree of potency and selectivity for individual metabotropic glutamate receptor subtypes, notably mGluR5. In particular, medical conditions associated with metabotropic glutamate receptors and therefore targeted by the invention compds. include stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, and Alzheimer's disease. Several hundred specific examples are individually prepared and/or claimed. A variety of intermediates were also prepared. For instance, 5-methylpyrid-2-ylamidoxime was prepared from 2-bromo-5-methylpyridine by Zn- and Pd-complex-mediated cyanation (56%) and reaction of the resulting nitrile with NH₂OH.HCl (60%). Cyclization of the amidoxime with 3-cyanobenzoyl chloride (86%) gave invention compound II. In a bioassay for mGluR5 antagonism in primary astrocyte cultures from rats, the invention compds. I had IC₅₀ values in the range of 11 to 9140 nM.

IT **327056-22-4P**, 3-(2-Pyridyl)-5-(3-fluoro-5-cyanophenyl)-1,2,4-oxadiazole **327056-26-8P**, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole **327056-37-1P**, 3-(2-Pyridyl)-5-(2-bromo-5-methoxyphenyl)-1,2,4-oxadiazole **453566-27-3P**, 3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole **453566-32-0P**, 3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole **453566-34-2P**, 3-(2-Pyridyl)-5-(5-bromo-2-methoxyphenyl)-1,2,4-oxadiazole **453566-35-3P**, 3-(2-Pyridyl)-5-(5-bromo-2-fluorophenyl)-1,2,4-oxadiazole **453566-46-6P**, 3-(2-Pyridyl)-5-(3-cyano-5-methylphenyl)-1,2,4-oxadiazole **453566-48-8P**, 3-(2-Pyridyl)-5-(3-fluoro-5-bromophenyl)-1,2,4-oxadiazole **453566-50-2P**, 3-(5-Fluoro-2-pyridyl)-5-(3-fluoro-5-bromophenyl)-1,2,4-oxadiazole **453566-51-3P**, 3-(2-Pyridyl)-5-[3-allyloxy-5-(methoxycarbonyl)phenyl]-1,2,4-oxadiazole **453566-52-4P**, 3-(2-Pyridyl)-5-[3-iodo-5-(methoxycarbonyl)phenyl]-1,2,4-oxadiazole **453566-53-5P**, 3-(2-Pyridyl)-5-[3-methoxy-5-(methoxycarbonyl)phenyl]-1,2,4-oxadiazole **453566-54-6P**, 3-(2-Pyridyl)-5-(3-bromo-5-cyanophenyl)-1,2,4-oxadiazole **453566-55-7P**, 3-(2-Pyridyl)-5-(5-cyano-3-iodophenyl)-1,2,4-oxadiazole **453566-86-4P**, 3-(2-Pyridyl)-5-(3-cyano-5-nitrophenyl)-1,2,4-oxadiazole **453566-87-5P**, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-nitrophenyl)-1,2,4-oxadiazole **453567-04-9P**, 3-(5-Fluoropyrid-2-yl)-5-(3-bromophenyl)-1,2,4-oxadiazole **453567-36-7P**, 3-(5-Fluoro-2-pyridyl)-5-[3-fluoro-5-(3-pyridyl)phenyl]-1,2,4-oxadiazole **453567-41-4P**,


3-(Pyrid-2-yl)-5-[3-fluoro-5-(methylthio)phenyl]-1,2,4-oxadiazole
453567-96-9P, 3-(2-Pyridyl)-5-(3-cyano-5-vinylphenyl)-1,2,4-oxadiazole **453567-99-2P 453568-01-9P**,
 3-(2-Pyridyl)-5-(3-carboxy-5-methoxyphenyl)-1,2,4-oxadiazole **453568-02-0P**, 3-(2-Pyridyl)-5-[3-(carboxamido)-5-methoxyphenyl]-1,2,4-oxadiazole **453568-04-2P**, 3-(2-Pyridyl)-5-(3-allyloxy-5-cyanophenyl)-1,2,4-oxadiazole **453568-05-3P**, 3-(2-Pyridyl)-5-(3-cyano-5-hydroxyphenyl)-1,2,4-oxadiazole **453568-20-2P**,
 3-(5-Fluoropyrid-2-yl)-5-(3-amino-5-cyanophenyl)-1,2,4-oxadiazole **453568-31-5P**, 3-(5-Fluoropyrid-2-yl)-5-[3-fluoro-5-(1H-tetrazol-5-yl)phenyl]-1,2,4-oxadiazole

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyridyl- and phenyl-substituted oxadiazoles and analogs as metabotropic glutamate receptor antagonists for inhibiting neuronal damage)


RN 327056-22-4 CAPLUS

CN Benzonitrile, 3-fluoro-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
 (CA INDEX NAME)




RN 327056-26-8 CAPLUS

CN Benzonitrile, 3-fluoro-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-37-1 CAPLUS

CN Pyridine, 2-[5-(2-bromo-5-methoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453566-27-3 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-(3-bromophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 453566-32-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 453566-34-2 CAPLUS

CN Pyridine, 2-[5-(5-bromo-2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 453566-35-3 CAPLUS

CN Pyridine, 2-[5-(5-bromo-2-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 453566-46-6 CAPLUS

CN Benzonitrile, 3-methyl-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 453566-48-8 CAPLUS

CN Pyridine, 2-[5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA
INDEX NAME)




RN 453566-50-2 CAPLUS

CN Pyridine, 2-[5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]-5-fluoro-
(9CI) (CA INDEX NAME)




RN 453566-51-3 CAPLUS

CN Benzoic acid, 3-(2-propenyloxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-,
methyl ester (9CI) (CA INDEX NAME)




RN 453566-52-4 CAPLUS

CN Benzoic acid, 3-iodo-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 453566-53-5 CAPLUS

CN Benzoic acid, 3-methoxy-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 453566-54-6 CAPLUS

CN Benzonitrile, 3-bromo-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453566-55-7 CAPLUS

CN Benzonitrile, 3-iodo-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453566-86-4 CAPLUS

CN Benzonitrile, 3-nitro-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453566-87-5 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-nitro- (9CI) (CA INDEX NAME)




RN 453567-04-9 CAPLUS

CN Pyridine, 2-[5-(3-bromophenyl)-1,2,4-oxadiazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 453567-36-7 CAPLUS

CN Pyridine, 5-fluoro-2-[5-[3-fluoro-5-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453567-41-4 CAPLUS

CN Pyridine, 2-[5-[3-fluoro-5-(methylthio)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 453567-96-9 CAPLUS

CN Benzonitrile, 3-ethenyl-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 453567-99-2 CAPLUS

CN Benzoic acid, 3-(2-propenyloxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-
(9CI) (CA INDEX NAME)




RN 453568-01-9 CAPLUS

CN Benzoic acid, 3-methoxy-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 453568-02-0 CAPLUS

CN Benzamide, 3-methoxy-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-04-2 CAPLUS

CN Benzonitrile, 3-(2-propenyloxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-05-3 CAPLUS

CN Benzonitrile, 3-hydroxy-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-20-2 CAPLUS

CN Benzonitrile, 3-amino-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



RN 453568-31-5 CAPLUS

CN Pyridine, 5-fluoro-2-[5-[3-fluoro-5-(1H-tetrazol-5-yl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



IT **27199-42-4P**, 3-(2-Pyridyl)-5-(2-chlorophenyl)-1,2,4-oxadiazole
327056-07-5P, 3-(2-Pyridyl)-5-(3,5-dichlorophenyl)-1,2,4-oxadiazole
327056-08-6P, 3-(2-Pyridyl)-5-(3-chlorophenyl)-1,2,4-oxadiazole
327056-09-7P, 3-(2-Pyridyl)-5-(3-methoxyphenyl)-1,2,4-oxadiazole
327056-10-0P, 3-(2-Pyridyl)-5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole
327056-11-1P, 3-(2-Pyridyl)-5-(3-fluorophenyl)-1,2,4-oxadiazole
327056-12-2P, 3-(2-Pyridyl)-5-(3-methylphenyl)-1,2,4-oxadiazole
327056-14-4P, 3-(2-Pyridyl)-5-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole
327056-15-5P, 3-(2-Pyridyl)-5-(2,3-difluorophenyl)-1,2,4-oxadiazole
327056-16-6P, 3-(2-Pyridyl)-5-(2,5-difluorophenyl)-1,2,4-oxadiazole
327056-17-7P, 3-(2-Pyridyl)-5-(3,5-difluorophenyl)-1,2,4-oxadiazole
327056-18-8P, 3-(2-Pyridyl)-5-(3-cyanophenyl)-1,2,4-oxadiazole
327056-19-9P, 3-(2-Pyridyl)-5-(3,5-dimethoxyphenyl)-1,2,4-oxadiazole
327056-20-2P, 3-(2-Pyridyl)-5-(2,3-dichlorophenyl)-1,2,4-oxadiazole
327056-21-3P, 3-(2-Pyridyl)-5-(3-chloro-5-cyanophenyl)-1,2,4-oxadiazole
327056-23-5P, 3-(2-Pyridyl)-5-(3-chloro-5-fluorophenyl)-1,2,4-oxadiazole
327056-24-6P, 3-(5-Chloropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole
327056-25-7P, 3-(5-Fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole
327056-27-9P, 3-(3-Fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole
327056-28-0P, 3-(5-Fluoropyrid-2-yl)-5-(3,5-dimethoxyphenyl)-1,2,4-oxadiazole
327056-29-1P, 3-(5-Methoxypyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole
327056-31-5P, 3-(3-Chloro-5-trifluoromethylpyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole
327056-32-6P, 3-(2-Pyridyl)-5-(5-chloro-2-methoxyphenyl)-1,2,4-oxadiazole
327056-33-7P, 3-(2-Pyridyl)-5-(2,3-dimethoxyphenyl)-1,2,4-oxadiazole
327056-34-8P, 3-(2-Pyridyl)-5-[2-chloro-5-(methylthio)phenyl]-1,2,4-oxadiazole
327056-35-9P, 3-(2-Pyridyl)-5-(3-phenoxyphenyl)-1,2,4-oxadiazole
327056-36-0P, 3-(2-Pyridyl)-5-(3-benzoylphenyl)-1,2,4-oxadiazole
327056-38-2P, 3-(2-Pyridyl)-5-[2-chloro-5-(trifluoromethyl)phenyl]-1,2,4-oxadiazole
327056-39-3P, 3-(2-Pyridyl)-5-(3,4,5-trifluorophenyl)-1,2,4-oxadiazole

327056-40-6P, 3-(2-Pyridyl)-5-(2,5,6-trifluorophenyl)-1,2,4-oxadiazole **327056-41-7P**, 3-(Pyrid-2-yl)-5-(2-hydroxyphenyl)-1,2,4-oxadiazole **327056-42-8P**, 3-(2-Pyridyl)-5-(5-chloro-2-hydroxyphenyl)-1,2,4-oxadiazole **327056-43-9P**, 3-(2-Pyridyl)-5-(2-aminophenyl)-1,2,4-oxadiazole **327056-44-0P**, 3-(2-Pyridyl)-5-(2-amino-5-chlorophenyl)-1,2,4-oxadiazole **453566-23-9P**, 3-(5-Methylpyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole **453566-24-0P**, 3-(5-Cyanopyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole **453566-30-8P**, 3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole **453566-36-4P**, 3-(2-Pyridyl)-5-(5-cyano-2-fluorophenyl)-1,2,4-oxadiazole **453566-49-9P**, 3-(2-Pyridyl)-5-(3-iodo-5-bromophenyl)-1,2,4-oxadiazole **453566-56-8P**, 3-(2-Pyridyl)-5-[3-(N,N-dimethylamino)phenyl]-1,2,4-oxadiazole **453566-57-9P**, 3-(5-Chloropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole **453566-58-0P**, 3-(5-Chloropyrid-2-yl)-5-(3-cyano-5-chlorophenyl)-1,2,4-oxadiazole **453566-59-1P**, 3-(5-Chloropyrid-2-yl)-5-(3-chloro-5-fluorophenyl)-1,2,4-oxadiazole **453566-60-4P**, 3-(5-Chloropyrid-2-yl)-5-(3-cyano-5-methoxyphenyl)-1,2,4-oxadiazole **453566-62-6P**, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-chlorophenyl)-1,2,4-oxadiazole **453566-63-7P**, 3-(5-Fluoropyrid-2-yl)-5-(3-fluoro-5-chlorophenyl)-1,2,4-oxadiazole **453566-64-8P**, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-methoxyphenyl)-1,2,4-oxadiazole **453566-65-9P**, 3-(5-Cyanopyrid-2-yl)-5-(3-cyano-5-chlorophenyl)-1,2,4-oxadiazole **453566-66-0P**, 3-(5-Cyanopyrid-2-yl)-5-(3-fluoro-5-chlorophenyl)-1,2,4-oxadiazole **453566-67-1P**, 3-(5-Cyanopyrid-2-yl)-5-(3-cyano-5-methoxyphenyl)-1,2,4-oxadiazole **453566-68-2P**, 3-(5-Fluoropyrid-2-yl)-5-(3,5-dicyanophenyl)-1,2,4-oxadiazole **453566-69-3P**, 3-[3-(4-Dimethylaminobutoxy)pyrid-2-yl]-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole **453566-73-9P**, 3-[3-(5-Dimethylaminopentyloxy)pyrid-2-yl]-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole **453566-76-2P**, 3-[3-(6-Dimethylaminohexyloxy)pyrid-2-yl]-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole **453566-78-4P**, 3-(5-Fluoropyrid-2-yl)-5-[5-fluoro-3-(methylthio)phenyl]-1,2,4-oxadiazole **453566-80-8P**, 3-(2-Pyridyl)-5-(3-fluoro-5-trifluoromethylphenyl)-1,2,4-oxadiazole **453566-81-9P**, 3-(5-Fluoro-2-pyridyl)-5-(3-fluoro-5-trifluoromethylphenyl)-1,2,4-oxadiazole **453566-82-0P**, 3-(5-Cyanopyrid-2-yl)-5-(3-alloxy-5-cyanophenyl)-1,2,4-oxadiazole **453566-83-1P**, 3-(5-Fluoropyrid-2-yl)-5-(3-alloxy-5-cyanophenyl)-1,2,4-oxadiazole **453566-84-2P**, 3-(5-Cyanopyrid-2-yl)-5-(3-cyano-5-propoxyphenyl)-1,2,4-oxadiazole **453566-85-3P**, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-propoxyphenyl)-1,2,4-oxadiazole **453566-88-6P**, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-dimethylaminophenyl)-1,2,4-oxadiazole **453566-89-7P**, 3-(5-Fluoropyrid-2-yl)-5-[3-cyano-5-(2-methoxyethoxy)phenyl]-1,2,4-oxadiazole **453566-90-0P**, 3-(5-Fluoropyrid-2-yl)-5-[3-cyano-5-(1H-imidazol-1-ylmethyl)phenyl]-1,2,4-oxadiazole **453566-91-1P**, 3-(2-Pyridyl)-5-[3-cyano-5-(methoxymethyl)phenyl]-1,2,4-oxadiazole **453566-95-5P**, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-ethoxyphenyl)-1,2,4-oxadiazole **453566-96-6P**, 3-(5-Cyanopyrid-2-yl)-5-(3-cyano-5-ethoxyphenyl)-1,2,4-oxadiazole **453566-97-7P**, 3-(5-Chloropyrid-2-yl)-5-(3-allyloxy-5-cyanophenyl)-1,2,4-oxadiazole **453566-98-8P**, 3-(5-Chloropyrid-2-yl)-5-(3-cyano-5-propoxyphenyl)-1,2,4-oxadiazole **453566-99-9P**, 3-(5-Chloropyrid-2-yl)-5-(3-cyano-5-ethoxyphenyl)-1,2,4-oxadiazole **453567-00-5P**, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-hexyloxyphenyl)-1,2,4-oxadiazole **453567-01-6P**, 3-(5-Fluoropyrid-2-yl)-5-[3-cyano-5-

(methoxymethyl)phenyl]-1,2,4-oxadiazole **453567-02-7P**,
 3-(5-Fluoropyrid-2-yl)-5-(5-cyano-2-methoxyphenyl)-1,2,4-oxadiazole
453567-03-8P, 5-(5-Cyano-2-methoxyphenyl)-3-(5-cyanopyrid-2-yl)-
 1,2,4-oxadiazole **453567-15-2P**, 5-(4-Cyanophenyl)-3-(6-cyanopyrid-
 2-yl)-1,2,4-oxadiazole **453567-16-3P**, 5-(3-Cyano-5-
 trifluoromethoxyphenyl)-3-(2-pyridyl)-1,2,4-oxadiazole
453567-17-4P, 5-(3-Methoxycarbonyl-5-trifluoromethoxyphenyl)-3-(2-
 pyridyl)-1,2,4-oxadiazole **453567-18-5P**, 5-(3-Cyano-5-
 trifluoromethoxyphenyl)-3-(5-fluoropyrid-2-yl)-1,2,4-oxadiazole
453567-19-6P, 3-(5-Cyanopyrid-2-yl)-5-(3-cyano-5-
 trifluoromethoxyphenyl)-1,2,4-oxadiazole **453567-37-8P**,
 3-(5-Fluoro-2-pyridyl)-5-[3-bromo-5-(3-pyridyl)phenyl]-1,2,4-oxadiazole
453567-38-9P, 3-(5-Fluoro-2-pyridyl)-5-(3-fluoro-5-methoxyphenyl)-
 1,2,4-oxadiazole **453567-39-0P**, 3-(Pyrid-2-yl)-5-[3-cyano-5-
 (methylthio)phenyl]-1,2,4-oxadiazole **453567-40-3P**,
 3-(5-Fluoropyrid-2-yl)-5-[3-cyano-5-(methylthio)phenyl]-1,2,4-oxadiazole
453567-42-5P, 3-(Pyrid-2-yl)-5-[3-fluoro-5-(methylsulfinyl)phenyl]-
 1,2,4-oxadiazole **453567-43-6P**, 3-(Pyrid-2-yl)-5-[3-fluoro-5-
 (ethylthio)phenyl]-1,2,4-oxadiazole **453567-45-8P**,
 3-(Pyrid-2-yl)-5-[5-fluoro-3-(tert-butylthio)phenyl]-1,2,4-oxadiazole
453567-46-9P, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-methylphenyl)-
 1,2,4-oxadiazole **453567-47-0P**, 3-(5-Cyanopyrid-2-yl)-5-(3-cyano-
 5-methylphenyl)-1,2,4-oxadiazole **453567-49-2P**,
 3-(2-Pyridyl)-5-(5-cyano-2-methoxyphenyl)-1,2,4-oxadiazole
453567-50-5P, 3-(2-Pyridyl)-5-(2-cyano-5-methoxyphenyl)-1,2,4-
 oxadiazole **453567-52-7P**, 3-(2-Pyridyl)-5-[3-cyano-5-
 (methoxycarbonyl)phenyl]-1,2,4-oxadiazole **453567-54-9P**,
 3-(5-Fluoro-2-pyridyl)-5-(3-cyano-5-trifluoromethylphenyl)-1,2,4-
 oxadiazole **453567-56-1P**, 3-(2-Pyridyl)-5-[3-cyano-5-(4-
 pyridyl)phenyl]-1,2,4-oxadiazole **453567-57-2P**,
 3-(2-Pyridyl)-5-[2-methoxy-5-(4-pyridyl)phenyl]-1,2,4-oxadiazole
453567-58-3P, 3-(2-Pyridyl)-5-[2-fluoro-5-(4-pyridyl)phenyl]-1,2,4-
 oxadiazole **453567-59-4P**, 3-(2-Pyridyl)-5-[3-fluoro-5-(4-
 pyridyl)phenyl]-1,2,4-oxadiazole **453567-60-7P**,
 3-(2-Pyridyl)-5-[3-fluoro-5-(3-pyridyl)phenyl]-1,2,4-oxadiazole
453567-61-8P, 3-(2-Pyridyl)-5-[2-fluoro-5-(3-pyridyl)phenyl]-1,2,4-
 oxadiazole **453567-62-9P**, 3-(2-Pyridyl)-5-[2-methoxy-5-(3-
 pyridyl)phenyl]-1,2,4-oxadiazole **453567-63-0P**,
 3-(2-Pyridyl)-5-[3-cyano-5-(3-pyridyl)phenyl]-1,2,4-oxadiazole
453567-66-3P, 3-(5-Cyanopyrid-2-yl)-5-[3-(pyrid-3-yl)phenyl]-1,2,4-
 oxadiazole **453567-67-4P**, 3-(5-Cyanopyrid-2-yl)-5-[3-(pyrid-3-
 yl)phenyl]-1,2,4-oxadiazole dihydrochloride **453567-68-5P**,
 3-(5-Cyanopyrid-2-yl)-5-[3-fluoro-5-(pyrid-3-yl)phenyl]-1,2,4-oxadiazole
453567-69-6P, 3-(5-Cyanopyrid-2-yl)-5-[3-fluoro-5-(pyrid-3-
 yl)phenyl]-1,2,4-oxadiazole dihydrochloride **453567-70-9P**,
 3-(2-Pyridyl)-5-[3-(3-fluorophenyl)-5-fluorophenyl]-1,2,4-oxadiazole
453567-71-0P, 3-(2-Pyridyl)-5-[3-cyano-5-(3-thienyl)phenyl]-1,2,4-
 oxadiazole **453567-76-5P**, 3-(2-Pyridyl)-5-[3-cyano-5-(5-
 pyrimidyl)phenyl]-1,2,4-oxadiazole **453567-77-6P**,
 3-(2-Pyridyl)-5-[3-cyano-5-(3-aminophenyl)phenyl]-1,2,4-oxadiazole
453567-78-7P, 3-(2-Pyridyl)-5-[3-cyano-5-(3-fluorophenyl)phenyl]-
 1,2,4-oxadiazole **453567-80-1P**, 3-(5-Fluoropyrid-2-yl)-5-[3-(3-
 pyridyl)phenyl]-1,2,4-oxadiazole **453567-90-3P**,
 3-(2-Pyridyl)-5-[3-cyano-5-(2-pyridyl)phenyl]-1,2,4-oxadiazole
453567-91-4P, 3-(2-Pyridyl)-5-[2-methoxy-5-(2-pyridyl)phenyl]-
 1,2,4-oxadiazole **453567-92-5P**, 3-(2-Pyridyl)-5-[2-fluoro-5-(2-
 pyridyl)phenyl]-1,2,4-oxadiazole **453567-93-6P**,
 3-(2-Pyridyl)-5-(3-aminomethyl-5-cyanophenyl)-1,2,4-oxadiazole

453567-97-0P, 3-(2-Pyridyl)-5-[3-cyano-5-(2-hydroxyethyl)phenyl]-1,2,4-oxadiazole **453567-98-1P**, 3-(2-Pyridyl)-5-[3-cyano-5-(2,3-dichloropropoxy)phenyl]-1,2,4-oxadiazole **453568-03-1P**, 3-(2-Pyridyl)-5-(3-cyano-5-methoxyphenyl)-1,2,4-oxadiazole **453568-06-4P**, 3-(2-Pyridyl)-5-[3-cyano-5-[2-(N,N-dimethylamino)ethoxy]phenyl]-1,2,4-oxadiazole **453568-07-5P**, 3-(2-Pyridyl)-5-[3-cyano-5-[3-(N,N-dimethylamino)propoxy]phenyl]-1,2,4-oxadiazole **453568-08-6P**, 3-(2-Pyridyl)-5-[3-cyano-5-(2-aminoethoxy)phenyl]-1,2,4-oxadiazole **453568-09-7P**, 3-(2-Pyridyl)-5-(3-cyano-5-propoxyphenyl)-1,2,4-oxadiazole **453568-10-0P**, 3-(2-Pyridyl)-5-[5-cyano-3-(3-hydroxypropyn-1-yl)phenyl]-1,2,4-oxadiazole **453568-13-3P**, 3-(2-Pyridyl)-5-[2-(N-methylamino)phenyl]-1,2,4-oxadiazole **453568-14-4P**, 3-(2-Pyridyl)-5-[3-cyano-5-(2-hydroxyethoxy)phenyl]-1,2,4-oxadiazole **453568-15-5P**, 3-(2-Pyridyl)-5-(3-cyano-5-isopropoxyphenyl)-1,2,4-oxadiazole **453568-16-6P**, 3-(2-Pyridyl)-5-(3-cyano-5-ethoxyphenyl)-1,2,4-oxadiazole **453568-17-7P**, 3-(2-Pyridyl)-5-[3-cyano-5-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazole **453568-18-8P**, 3-(2-Pyridyl)-5-(3-cyano-5-cyclopropylmethoxyphenyl)-1,2,4-oxadiazole **453568-19-9P**, 3-(2-Pyridyl)-5-(3-amino-5-cyanophenyl)-1,2,4-oxadiazole **453568-21-3P**, 3-(2-Pyridyl)-5-[3-cyano-5-(trifluoromethylsulfonyloxy)phenyl]-1,2,4-oxadiazole **453568-22-4P**, 3-(2-Pyridyl)-5-[3-cyano-5-(2-methoxy-2-oxoethoxy)phenyl]-1,2,4-oxadiazole **453568-23-5P**, 3-(2-Pyridyl)-5-[3-cyano-5-(2-tert-butoxy-2-oxoethoxy)phenyl]-1,2,4-oxadiazole **453568-24-6P**, 3-(2-Pyridyl)-5-[3-cyano-5-(methoxymethoxy)phenyl]-1,2,4-oxadiazole **453568-25-7P**, 3-(2-Pyridyl)-5-[3-cyano-5-(2-methoxyethoxy)phenyl]-1,2,4-oxadiazole **453568-26-8P**, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-cyclopentylaminophenyl)-1,2,4-oxadiazole **453568-27-9P**, 3-(2-Pyridyl)-5-(3-cyano-5-hexyloxyphenyl)-1,2,4-oxadiazole **453568-28-0P**, 3-(2-Pyridyl)-5-[3-cyano-5-[[(dimethylamino) carbonyl]oxy]phenyl]-1,2,4-oxadiazole **453568-29-1P**, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-ethylaminophenyl)-1,2,4-oxadiazole **453568-30-4P**, 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-diethylaminophenyl)-1,2,4-oxadiazole **453568-32-6P**, 5-[3-Fluoro-5-(1-methyl-1H-tetrazol-5-yl)phenyl]-3-(5-fluoropyrid-2-yl)-1,2,4-oxadiazole **453568-33-7P**, 3-(5-Fluoro-2-pyridyl)-5-[3-(1-benzyl-1,2,5,6-tetrahydropyridin-3-yl)-5-fluorophenyl]-1,2,4-oxadiazole **453568-34-8P**, 3-(5-Fluoro-2-pyridyl)-5-[3-fluoro-5-(1H-imidazol-4-yl)phenyl]-1,2,4-oxadiazole **453568-39-3P**, 3-(2-Pyridyl)-5-[3-(1H-imidazol-1-yl)-5-(methylthio)phenyl]-1,2,4-oxadiazole **453568-40-6P**, 3-(2-Pyridyl)-5-[3-(1H-imidazol-1-yl)-5-(methylthio)phenyl]-1,2,4-oxadiazole hydrochloride **453568-43-9P** **453568-44-0P**, 3-(2-Pyridyl)-5-[3-cyano-5-(1H-imidazol-1-yl)phenyl]-1,2,4-oxadiazole hydrochloride **453568-81-5P**, 3-(Pyrid-2-yl)-5-[3-methoxy-5-(pyrid-3-yl)phenyl]-1,2,4-oxadiazole **453568-82-6P**, 3-(5-Fluoropyrid-2-yl)-5-[3-(methoxycarbonyl)-5-(pyrid-3-yl)phenyl]-1,2,4-oxadiazole **453568-83-7P**, 3-(5-Fluoropyrid-2-yl)-5-[3-methoxy-5-(pyrid-3-yl)phenyl]-1,2,4-oxadiazole **453568-84-8P**, 3-(5-Cyanopyrid-2-yl)-5-[3-methoxy-5-(pyrid-3-yl)phenyl]-1,2,4-oxadiazole **453568-88-2P**, 3-(2-Pyridyl)-5-(3-cyano-5-trifluoromethylphenyl)-1,2,4-oxadiazole


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyridyl- and phenyl-substituted oxadiazoles and analogs as metabotropic glutamate receptor antagonists for

inhibiting neuronal damage)


RN 27199-42-4 CAPLUS

CN Pyridine, 2-[5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-07-5 CAPLUS

CN Pyridine, 2-[5-(3,5-dichlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-08-6 CAPLUS

CN Pyridine, 2-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-09-7 CAPLUS

CN Pyridine, 2-[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-10-0 CAPLUS

CN Pyridine, 2-[5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-11-1 CAPLUS

CN Pyridine, 2-[5-(3-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-12-2 CAPLUS

CN Pyridine, 2-[5-(3-methylphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-14-4 CAPLUS

CN Pyridine, 2-[5-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-15-5 CAPLUS

CN Pyridine, 2-[5-(2,3-difluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-16-6 CAPLUS

CN Pyridine, 2-[5-(2,5-difluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-17-7 CAPLUS

CN Pyridine, 2-[5-(3,5-difluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-18-8 CAPLUS

CN Benzonitrile, 3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-19-9 CAPLUS

CN Pyridine, 2-[5-(3,5-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-20-2 CAPLUS


CN Pyridine, 2-[5-(2,3-dichlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-21-3 CAPLUS
 CN Benzonitrile, 3-chloro-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
 (CA INDEX NAME)




RN 327056-23-5 CAPLUS
 CN Pyridine, 2-[5-(3-chloro-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA
 INDEX NAME)



RN 327056-24-6 CAPLUS
 CN Benzonitrile, 3-[3-(5-chloro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
 (CA INDEX NAME)




RN 327056-25-7 CAPLUS
 CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
 (CA INDEX NAME)




RN 327056-27-9 CAPLUS

CN Benzonitrile, 3-[3-(3-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 327056-28-0 CAPLUS

CN Pyridine, 2-[5-(3,5-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]-5-fluoro- (9CI)
(CA INDEX NAME)




RN 327056-29-1 CAPLUS

CN Benzonitrile, 3-[3-(5-methoxy-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 327056-31-5 CAPLUS

CN Benzonitrile, 3-[3-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-32-6 CAPLUS

CN Pyridine, 2-[5-(5-chloro-2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 327056-33-7 CAPLUS

CN Pyridine, 2-[5-(2,3-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA
INDEX NAME)




RN 327056-34-8 CAPLUS

CN Pyridine, 2-[5-[2-chloro-5-(methylthio)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 327056-35-9 CAPLUS

CN Pyridine, 2-[5-(3-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX
NAME)




RN 327056-36-0 CAPLUS

CN Methanone, phenyl[3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI)
(CA INDEX NAME)




RN 327056-38-2 CAPLUS

CN Pyridine, 2-[5-[2-chloro-5-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 327056-39-3 CAPLUS

CN Pyridine, 2-[5-(3,4,5-trifluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA
INDEX NAME)




RN 327056-40-6 CAPLUS

CN Pyridine, 2-[5-(2,3,6-trifluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA
INDEX NAME)




RN 327056-41-7 CAPLUS

CN Phenol, 2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-42-8 CAPLUS

CN Phenol, 4-chloro-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-43-9 CAPLUS

CN Benzenamine, 2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-44-0 CAPLUS

CN Benzenamine, 4-chloro-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453566-23-9 CAPLUS

CN Benzonitrile, 3-[3-(5-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 453566-24-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-(3-cyanophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 453566-30-8 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 453566-36-4 CAPLUS

CN Benzonitrile, 4-fluoro-3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 453566-49-9 CAPLUS

CN Pyridine, 2-[5-(3-bromo-5-iodophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453566-56-8 CAPLUS

CN Benzenamine, N,N-dimethyl-3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453566-57-9 CAPLUS

CN Benzonitrile, 3-[3-(5-chloro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 453566-58-0 CAPLUS

CN Benzonitrile, 3-chloro-5-[3-(5-chloro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453566-59-1 CAPLUS

CN Pyridine, 5-chloro-2-[5-(3-chloro-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 453566-60-4 CAPLUS

CN Benzonitrile, 3-[3-(5-chloro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-methoxy-
(9CI) (CA INDEX NAME)




RN 453566-62-6 CAPLUS

CN Benzonitrile, 3-chloro-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-
(9CI) (CA INDEX NAME)




RN 453566-63-7 CAPLUS

CN Pyridine, 2-[5-(3-chloro-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]-5-fluoro-
(9CI) (CA INDEX NAME)




RN 453566-64-8 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-methoxy-
(9CI) (CA INDEX NAME)




RN 453566-65-9 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-(3-chloro-5-cyanophenyl)-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 453566-66-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-(3-chloro-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 453566-67-1 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-(3-cyano-5-methoxyphenyl)-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 453566-68-2 CAPLUS

CN 1,3-Benzenedicarbonitrile, 5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453566-69-3 CAPLUS

CN Benzonitrile, 3-[3-[3-[4-(dimethylamino)butoxy]-2-pyridinyl]-1,2,4-oxadiazol-5-yl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 453566-73-9 CAPLUS

CN Benzonitrile, 3-[3-[3-[[5-(dimethylamino)pentyl]oxy]-2-pyridinyl]-1,2,4-oxadiazol-5-yl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 453566-76-2 CAPLUS

CN Benzonitrile, 3-[3-[3-[[6-(dimethylamino)hexyl]oxy]-2-pyridinyl]-1,2,4-oxadiazol-5-yl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 453566-78-4 CAPLUS

CN Pyridine, 5-fluoro-2-[5-[3-fluoro-5-(methylthio)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453566-80-8 CAPLUS

CN Pyridine, 2-[5-[3-fluoro-5-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453566-81-9 CAPLUS

CN Pyridine, 5-fluoro-2-[5-[3-fluoro-5-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453566-82-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-[3-cyano-5-(2-propenyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453566-83-1 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 453566-84-2 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-(3-cyano-5-propoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453566-85-3 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-propoxy- (9CI) (CA INDEX NAME)




RN 453566-88-6 CAPLUS

CN Benzonitrile, 3-(dimethylamino)-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453566-89-7 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 453566-90-0 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(1H-imidazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 453566-91-1 CAPLUS

CN Benzonitrile, 3-(methoxymethyl)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453566-95-5 CAPLUS

CN Benzonitrile, 3-ethoxy-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453566-96-6 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-(3-cyano-5-ethoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453566-97-7 CAPLUS

CN Benzonitrile, 3-[3-(5-chloro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(2-propenyloxy)- (9CI) (CA INDEX NAME)




RN 453566-98-8 CAPLUS

CN Benzonitrile, 3-[3-(5-chloro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-propoxy- (9CI) (CA INDEX NAME)




RN 453566-99-9 CAPLUS

CN Benzonitrile, 3-[3-(5-chloro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-ethoxy- (9CI) (CA INDEX NAME)




RN 453567-00-5 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(hexyloxy)- (9CI) (CA INDEX NAME)




RN 453567-01-6 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 453567-02-7 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 453567-03-8 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-(5-cyano-2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453567-15-2 CAPLUS

CN 2-Pyridinecarbonitrile, 6-[5-(4-cyanophenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 453567-16-3 CAPLUS

CN Benzonitrile, 3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 453567-17-4 CAPLUS

CN Benzoic acid, 3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(trifluoromethoxy)-, methyl ester (9CI) (CA INDEX NAME)




RN 453567-18-5 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 453567-19-6 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-[3-cyano-5-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453567-37-8 CAPLUS

CN Pyridine, 2-[5-[3-bromo-5-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 453567-38-9 CAPLUS

CN Pyridine, 5-fluoro-2-[5-(3-fluoro-5-methoxyphenyl)-1,2,4-oxadiazol-3-yl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 453567-39-0 CAPLUS

CN Benzonitrile, 3-(methylthio)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453567-40-3 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(methylthio)- (9CI) (CA INDEX NAME)




RN 453567-42-5 CAPLUS

CN Pyridine, 2-[5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-3-yl]-5-(methylsulfinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 453567-43-6 CAPLUS

CN Pyridine, 2-[5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-3-yl]-5-(ethylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 453567-45-8 CAPLUS

CN Pyridine, 2-[5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-3-yl]-5-(1,1-dimethylethylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 453567-46-9 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-methyl- (9CI) (CA INDEX NAME)




RN 453567-47-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-(3-cyano-5-methylphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453567-49-2 CAPLUS

CN Benzonitrile, 4-methoxy-3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453567-50-5 CAPLUS

CN Benzonitrile, 4-methoxy-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453567-52-7 CAPLUS

CN Benzoic acid, 3-cyano-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 453567-54-9 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 453567-56-1 CAPLUS

CN Benzonitrile, 3-(4-pyridinyl)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453567-57-2 CAPLUS


CN Pyridine, 2-[5-[2-methoxy-5-(4-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453567-58-3 CAPLUS

CN Pyridine, 2-[5-[2-fluoro-5-(4-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)

RN 453567-59-4 CAPLUS


CN Pyridine, 2-[5-[3-fluoro-5-(4-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)

RN 453567-60-7 CAPLUS

CN Pyridine, 2-[5-[3-fluoro-5-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)

RN 453567-61-8 CAPLUS

CN Pyridine, 2-[5-[2-fluoro-5-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 453567-62-9 CAPLUS

CN Pyridine, 2-[5-[2-methoxy-5-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 453567-63-0 CAPLUS

CN Benzonitrile, 3-(3-pyridinyl)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-
(9CI) (CA INDEX NAME)




RN 453567-66-3 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-[3-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)



RN 453567-67-4 CAPLUS


CN 3-Pyridinecarbonitrile, 6-[5-[3-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]-
, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 453567-68-5 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-[3-fluoro-5-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 453567-69-6 CAPLUS


CN 3-Pyridinecarbonitrile, 6-[5-[3-fluoro-5-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 453567-70-9 CAPLUS


CN Pyridine, 2-[5-(3',5-difluoro[1,1'-biphenyl]-3-yl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 453567-71-0 CAPLUS


CN Benzonitrile, 3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(3-thienyl)-
(9CI) (CA INDEX NAME)

RN 453567-76-5 CAPLUS

CN Benzonitrile, 3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(5-pyrimidinyl)-
(9CI) (CA INDEX NAME)


RN 453567-77-6 CAPLUS

CN [1,1'-Biphenyl]-3-carbonitrile, 3'-amino-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



RN 453567-78-7 CAPLUS


CN [1,1'-Biphenyl]-3-carbonitrile, 3'-fluoro-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453567-80-1 CAPLUS

CN Pyridine, 5-fluoro-2-[5-[3-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]-


(9CI) (CA INDEX NAME)




RN 453567-90-3 CAPLUS

CN Benzonitrile, 3-(2-pyridinyl)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-
(9CI) (CA INDEX NAME)

RN 453567-91-4 CAPLUS


CN Pyridine, 2-[4-methoxy-3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]-
(9CI) (CA INDEX NAME)

RN 453567-92-5 CAPLUS

CN Pyridine, 2-[4-fluoro-3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]-
(9CI) (CA INDEX NAME)


RN 453567-93-6 CAPLUS

CN Benzonitrile, 3-(aminomethyl)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-
(9CI) (CA INDEX NAME)




RN 453567-97-0 CAPLUS

CN Benzonitrile, 3-(2-hydroxyethyl)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453567-98-1 CAPLUS

CN Benzonitrile, 3-(2,3-dichloropropoxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-03-1 CAPLUS

CN Benzonitrile, 3-methoxy-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-06-4 CAPLUS

CN Benzonitrile, 3-[2-(dimethylamino)ethoxy]-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-07-5 CAPLUS

CN Benzonitrile, 3-[3-(dimethylamino)propoxy]-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-08-6 CAPLUS

CN Benzonitrile, 3-(2-aminoethoxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-09-7 CAPLUS

CN Benzonitrile, 3-propoxy-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-10-0 CAPLUS

CN Benzonitrile, 3-(3-hydroxy-1-propynyl)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-13-3 CAPLUS

CN Benzenamine, N-methyl-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-14-4 CAPLUS

CN Benzonitrile, 3-(2-hydroxyethoxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-15-5 CAPLUS

CN Benzonitrile, 3-(1-methylethoxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-16-6 CAPLUS

CN Benzonitrile, 3-ethoxy-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-17-7 CAPLUS

CN Benzonitrile, 3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 453568-18-8 CAPLUS

CN Benzonitrile, 3-(cyclopropylmethoxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-19-9 CAPLUS

CN Benzonitrile, 3-amino-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-21-3 CAPLUS

CN Methanesulfonic acid, trifluoro-, 3-cyano-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl ester (9CI) (CA INDEX NAME)




RN 453568-22-4 CAPLUS

CN Acetic acid, [3-cyano-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 453568-23-5 CAPLUS

CN Acetic acid, [3-cyano-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453568-24-6 CAPLUS

CN Benzonitrile, 3-(methoxymethoxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-25-7 CAPLUS


CN Benzonitrile, 3-(2-methoxyethoxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-
(9CI) (CA INDEX NAME)

RN 453568-26-8 CAPLUS

CN Benzonitrile, 3-(cyclopentylamino)-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-27-9 CAPLUS

CN Benzonitrile, 3-(hexyloxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
(CA INDEX NAME)


RN 453568-28-0 CAPLUS

CN Carbamic acid, dimethyl-, 3-cyano-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl ester (9CI) (CA INDEX NAME)




RN 453568-29-1 CAPLUS

CN Benzonitrile, 3-(ethylamino)-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-30-4 CAPLUS

CN Benzonitrile, 3-(diethylamino)-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-32-6 CAPLUS

CN Pyridine, 5-fluoro-2-[5-[3-fluoro-5-(1-methyl-1H-tetrazol-5-yl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453568-33-7 CAPLUS

CN Pyridine, 3-[3-fluoro-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]-1,2,5,6-tetrahydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 453568-34-8 CAPLUS

CN Pyridine, 5-fluoro-2-[5-[3-fluoro-5-(1H-imidazol-4-yl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453568-39-3 CAPLUS

CN Pyridine, 2-[5-[3-(1H-imidazol-1-yl)-5-(methylthio)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 453568-40-6 CAPLUS


CN Pyridine, 2-[5-[3-(1H-imidazol-1-yl)-5-(methylthio)phenyl]-1,2,4-oxadiazol-3-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 453568-43-9 CAPLUS

CN Benzonitrile, 3-(1H-imidazol-1-yl)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



RN 453568-44-0 CAPLUS


CN Benzonitrile, 3-(1H-imidazol-1-yl)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 453568-81-5 CAPLUS

CN Pyridine, 2-[5-[3-methoxy-5-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453568-82-6 CAPLUS

CN Benzoic acid, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 453568-83-7 CAPLUS

CN Pyridine, 5-fluoro-2-[5-[3-methoxy-5-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453568-84-8 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[5-[3-methoxy-5-(3-pyridinyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 453568-88-2 CAPLUS

CN Benzonitrile, 3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **453566-25-1P**, 3-(5-tert-Butoxycarbonyl-2-pyridyl)-5-(3-cyanophenyl)-1,2,4-oxadiazole **453566-26-2P**, 3-(5-Hydroxycarbonylpyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole **453566-28-4P**, 3-(5-tert-Butoxycarbonyl-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole **453566-29-5P**, 3-(5-Hydroxycarbonylpyrid-2-yl)-5-(3-bromophenyl)-1,2,4-oxadiazole **453566-31-9P**, 3-(5-tert-Butoxycarbonyl-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole **453566-33-1P**, 3-(5-tert-Butoxycarbonyl-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole **453567-53-8P**, 3-(2-Pyridyl)-5-(3-iodo-5-trifluoromethylphenyl)-1,2,4-oxadiazole **453567-55-0P**, 3-(5-Fluoro-2-pyridyl)-5-(3-iodo-5-trifluoromethylphenyl)-1,2,4-oxadiazole **453567-94-7P**, 3-(2-Pyridyl)-5-(3-bromomethyl-5-cyanophenyl)-1,2,4-oxadiazole **453568-00-8P**, 3-(2-Pyridyl)-5-(3-allyloxy-5-carboxamidophenyl)-1,2,4-oxadiazole **453568-35-9P**, 3-(5-Fluoro-2-pyridyl)-5-[3-fluoro-5-(1-trityl-1H-imidazol-4-yl)phenyl]-1,2,4-oxadiazole


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyridyl- and phenyl-substituted oxadiazoles)

and analogs as metabotropic glutamate receptor antagonists for
inhibiting neuronal damage)


RN 453566-25-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[5-(3-cyanophenyl)-1,2,4-oxadiazol-3-yl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453566-26-2 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[5-(3-cyanophenyl)-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 453566-28-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[5-(3-bromophenyl)-1,2,4-oxadiazol-3-yl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453566-29-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[5-(3-bromophenyl)-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 453566-31-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453566-33-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 453567-53-8 CAPLUS

CN Pyridine, 2-[5-[3-iodo-5-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453567-55-0 CAPLUS

CN Pyridine, 5-fluoro-2-[5-[3-iodo-5-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 453567-94-7 CAPLUS

CN Benzonitrile, 3-(bromomethyl)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 453568-00-8 CAPLUS

CN Benzamide, 3-(2-propenyloxy)-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-
(9CI) (CA INDEX NAME)



RN 453568-35-9 CAPLUS

CN Pyridine, 5-fluoro-2-[5-[3-fluoro-5-[1-(triphenylmethyl)-1H-imidazol-4-yl]phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




IT **453566-71-7**, 3-(3-Fluoropyrid-2-yl)-5-(3-fluoro-5-cyanophenyl)-
1,2,4-oxadiazole

RL: RCT (Reactant); RACT (Reactant or reagent)

(precursor; preparation of pyridyl- and phenyl-substituted oxadiazoles and
analogs as metabotropic glutamate receptor antagonists for inhibiting
neuronal damage)

RN 453566-71-7 CAPLUS

CN Benzonitrile, 3-fluoro-5-[3-(3-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]-
(9CI) (CA INDEX NAME)



IT **327056-50-8P**, 3-(2-Pyridyl)-5-(3-nitrophenyl)-1,2,4-oxadiazole


327056-52-0P, 3-(2-Pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridyl- and phenyl-substituted oxadiazoles and analogs as metabotropic glutamate receptor antagonists for inhibiting neuronal damage)


RN 327056-50-8 CAPLUS

CN Pyridine, 2-[5-(3-nitrophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 327056-52-0 CAPLUS

CN Pyridine, 2-[5-(3-bromophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:811834 CAPLUS

DN 136:93757

TI Liquid crystalline pyridine-containing 1,2,4-oxadiazoles

AU Karamysheva, Ludmila A.; Agafonova, Irina F.; Torgova, Sofia I.; Umanskii, Boris A.; Strigazzi, Alfredo

CS SSC RF "NIOPIK" (Organic Intermediates and Dyes Institute), Moscow, 103787, Russia

SO Molecular Crystals and Liquid Crystals Science and Technology, Section A: Molecular Crystals and Liquid Crystals (2001), 364, 547-556

CODEN: MCLCE9; ISSN: 1058-725X

PB Gordon & Breach Science Publishers

DT Journal

LA English

AB New mesomorphic 1,2,4-oxadiazoles containing as an electron-acceptor substituent the pyridine ring with different positions of the N atom with respect to the oxadiazole ring were synthesized. The reaction of the isonicotinic and nicotinic amidoximes with various acid chlorides smoothly provided the corresponding mesogenic 3-(4-pyridinyl)- and 3-(3-pyridinyl)-1,2,4-oxadiazoles. On the contrary with picolinic amidoxime as a starting material mainly noncyclized nonmesomorphic products were obtained. Temperature and dielec. characteristics of new pyridinic liquid crystals were measured and compared with analogous parameters of corresponding Ph (cyclohexyl) substituted oxadiazoles.

IT **387400-52-4P**

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP


(Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(preparation and liquid crystal and dielec. properties of)

RN 387400-52-4 CAPLUS

CN Pyridine, 2-[5-[4-(trans-4-pentylcyclohexyl)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **387400-51-3P**


RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(preparation and liquid crystal properties of)

RN 387400-51-3 CAPLUS

CN Pyridine, 2-[5-[4-(trans-4-propylcyclohexyl)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:137213 CAPLUS

DN 134:193438

TI Preparation of 3-(2-pyridyl)-5-phenyl substituted 1,2,4-oxadiazoles, 1,2-oxazoles and 1,2,4-triazoles as metabotropic glutamate receptor antagonists



IN Van Wagenen, Bradford C.; Stormann, Thomas M.; Moe, Scott T.; Sheehan, Susan M.; McLeod, Donald A.; Smith, Daryl L.; Isaac, Methvin Benjamin; Slassi, Abdelmalik

PA NPS Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012627	A1	20010222	WO 2000-US22618	20000818 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2381975	AA	20010222	CA 2000-2381975	20000818 <--
	EP 1210344	A1	20020605	EP 2000-955657	20000818
	EP 1210344	B1	20051019		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000013427	A	20020730	BR 2000-13427	20000818
	JP 2003507378	T2	20030225	JP 2001-517525	20000818
	EE 200200079	A	20030616	EE 2002-79	20000818
	NZ 517221	A	20040130	NZ 2000-517221	20000818
	AU 780191	B2	20050303	AU 2000-67824	20000818
	EP 1582519	A2	20051005	EP 2005-14788	20000818
	EP 1582519	A3	20051221		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AT 307129	E	20051115	AT 2000-955657	20000818
	ZA 2002001358	A	20030519	ZA 2002-1358	20020218
	NO 2002000823	A	20020417	NO 2002-823	20020219
	US 2003055085	A1	20030320	US 2002-76618	20020219
	US 6660753	B2	20031209		
	BG 106493	A	20030131	BG 2002-106493	20020307
	US 2005154027	A1	20050714	US 2003-699563	20031103
PRAI	US 1999-149464P	P	19990819		
	EP 2000-955657	A3	20000818		
	WO 2000-US22618	W	20000818		
	US 2001-269847P	P	20010221		
	US 2002-76618	A1	20020219		
OS	MARPAT 134:193438				
GI					



AB The title compds. [I; X, Y, Z = N, O, S, C, CO wherein at least one of X, Y, Z is a heteroatom; Ar1, Ar2 = heterocyclic, fused heterocyclic moiety, aromatic moiety] which act as antagonists at metabotropic glutamate receptors, and are useful for treating neurol. diseases and disorders, were prepared Thus, reacting 3-cyanobenzoyl chloride with


pyrid-2-ylamidoxime (preparation given) in pyridine afforded 64% II which showed IC50 of 43 nM in relation to CaR/mGluR5d and IC50 of 121 nM on the native receptor, mGluR5d.

IT 27199-42-4P 327056-07-5P 327056-08-6P
 327056-09-7P 327056-10-0P 327056-11-1P
 327056-12-2P 327056-14-4P 327056-15-5P
 327056-16-6P 327056-17-7P 327056-18-8P
 327056-19-9P 327056-20-2P 327056-21-3P
 327056-22-4P 327056-23-5P 327056-24-6P
 327056-25-7P 327056-26-8P 327056-27-9P
 327056-28-0P 327056-29-1P 327056-31-5P
 327056-32-6P 327056-33-7P 327056-34-8P
 327056-35-9P 327056-36-0P 327056-37-1P
 327056-38-2P 327056-39-3P 327056-40-6P
 327056-41-7P 327056-42-8P 327056-43-9P
 327056-44-0P 327056-50-8P 327056-52-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-(2-pyridyl)-5-Ph substituted 1,2,4-oxadiazoles, 1,2-oxazoles and 1,2,4-triazoles as metabotropic glutamate receptor antagonists)


RN 27199-42-4 CAPLUS

CN Pyridine, 2-[5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-07-5 CAPLUS

CN Pyridine, 2-[5-(3,5-dichlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-08-6 CAPLUS

CN Pyridine, 2-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-09-7 CAPLUS

CN Pyridine, 2-[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-10-0 CAPLUS

CN Pyridine, 2-[5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-11-1 CAPLUS

CN Pyridine, 2-[5-(3-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 327056-12-2 CAPLUS


CN Pyridine, 2-[5-(3-methylphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 327056-14-4 CAPLUS


CN Pyridine, 2-[5-[3-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (9CI)

(CA INDEX NAME)




RN 327056-15-5 CAPLUS

CN Pyridine, 2-[5-(2,3-difluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-16-6 CAPLUS

CN Pyridine, 2-[5-(2,5-difluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-17-7 CAPLUS

CN Pyridine, 2-[5-(3,5-difluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-18-8 CAPLUS

CN Benzonitrile, 3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-19-9 CAPLUS

CN Pyridine, 2-[5-(3,5-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-20-2 CAPLUS

CN Pyridine, 2-[5-(2,3-dichlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-21-3 CAPLUS

CN Benzonitrile, 3-chloro-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-22-4 CAPLUS

CN Benzonitrile, 3-fluoro-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-23-5 CAPLUS

CN Pyridine, 2-[5-(3-chloro-5-fluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-24-6 CAPLUS

CN Benzonitrile, 3-[3-(5-chloro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-25-7 CAPLUS

CN Benzonitrile, 3-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-26-8 CAPLUS

CN Benzonitrile, 3-fluoro-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-27-9 CAPLUS

CN Benzonitrile, 3-[3-(3-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 327056-28-0 CAPLUS

CN Pyridine, 2-[5-(3,5-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]-5-fluoro- (9CI)
(CA INDEX NAME)




RN 327056-29-1 CAPLUS

CN Benzonitrile, 3-[3-(5-methoxy-2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 327056-31-5 CAPLUS

CN Benzonitrile, 3-[3-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-32-6 CAPLUS

CN Pyridine, 2-[5-(5-chloro-2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 327056-33-7 CAPLUS

CN Pyridine, 2-[5-(2,3-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA
INDEX NAME)




RN 327056-34-8 CAPLUS

CN Pyridine, 2-[5-[2-chloro-5-(methylthio)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 327056-35-9 CAPLUS

CN Pyridine, 2-[5-(3-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX
NAME)




RN 327056-36-0 CAPLUS

CN Methanone, phenyl[3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI)
(CA INDEX NAME)




RN 327056-37-1 CAPLUS

CN Pyridine, 2-[5-(2-bromo-5-methoxyphenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA
INDEX NAME)




RN 327056-38-2 CAPLUS

CN Pyridine, 2-[5-[2-chloro-5-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-
(9CI) (CA INDEX NAME)




RN 327056-39-3 CAPLUS

CN Pyridine, 2-[5-(3,4,5-trifluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA
INDEX NAME)




RN 327056-40-6 CAPLUS

CN Pyridine, 2-[5-(2,3,6-trifluorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 327056-41-7 CAPLUS

CN Phenol, 2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-42-8 CAPLUS

CN Phenol, 4-chloro-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-43-9 CAPLUS

CN Benzenamine, 2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-44-0 CAPLUS

CN Benzenamine, 4-chloro-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)




RN 327056-50-8 CAPLUS

CN Pyridine, 2-[5-(3-nitrophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 327056-52-0 CAPLUS

CN Pyridine, 2-[5-(3-bromophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:718232 CAPLUS

DN 133:296449

TI Preparation of benzhydrylpiperazines and related compounds as
P-glycoprotein inhibitors for enhancing the antitumor activity of other
cytotoxic agents.

IN Arnold, Lee Daniel; Coe, Jotham Wadsworth; Kaneko, Takushi; Moyer, Mikel

Paul
 PA Pfizer Inc., USA
 SO U.S., 64 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6130217	A	20001010	US 1995-513880	19950920 <--
PRAI	US 1995-513880		19950920		
OS	MARPAT 133:296449				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB NR100R101R102 [R100 = Y1CH(Z1)(CH2)_nY2B1A1Q1, CH2C(OH)R103CH2CH2OQ1, etc.; R103 = alkyl; Y1 = O, CH2, CH2CH2, bond; Z1 = H, OH, CF3, NO2, alkoxy; n = 1, 2; Y2 = O, S, NH, NMe, CONH, bond; B1 = bond, (substituted) Ph; A1 = bond, alkylene, O, S, NH; Q1 = specified (substituted) azolyl, (fused) Ph, etc.; R101 = R100, H, alkyl, (substituted) alkenylphenyl, alkylphenyl; R102 = Q4, Q5, Q6, etc.; X9 = H, OH, Cl, F, alkoxy, CF3, alkyl; dotted line = optional double bond; n = 1, 2; Q = S, O; R101R102N = Q7, Q8, etc.; with provisos], were prepared as P-glycoprotein inhibitors (no data). Thus, 1-benzhydrylpiperazine and 2-[2-(oxiran-2-ylmethoxy)phenyl]benzothiazole were refluxed 16 h in EtOH to give 42% 1-(4-benzhydrylpiperazin-1-yl)-3-(2-benzothiazol-2-ylphenoxy)propan-2-ol.

IT **163296-44-4P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzhydrylpiperazines and related compds. as P-glycoprotein inhibitors for enhancing the antitumor activity of other cytotoxic agents)

RN 163296-44-4 CAPLUS
 CN Piperazine, 1-(diphenylmethyl)-4-[3-[2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenoxy]propyl]- (9CI) (CA INDEX NAME)




RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:191084 CAPLUS

DN 132:222538
 TI Preparation of 2-[(oxadiazolylpyridinyl)oxymethyl]- α -methoxyiminophenylacetamides as agrochemical fungicides
 IN Kirby, Neil Vincent; Canada, Emily Jane; Morrison, Irene Mae; Pieczko, Mary Elizabeth; Gustafson, Gary David; Mathieson, John Todd; Cooper, David Harry; Galka, Christopher Stanley; Adamski, Jenifer Lynn
 PA Dow Agrosiences. Llc, USA
 SO PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000015637	A1	20000323	WO 1999-US21346	19990916 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9962516	A1	20000403	AU 1999-62516	19990916 <--
	US 6133294	A	20001017	US 1999-397564	19990916 <--
	EP 1114045	A1	20010711	EP 1999-949693	19990916
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9915968	A	20010828	BR 1999-15968	19990916
	JP 2002524562	T2	20020806	JP 2000-570175	19990916
PRAI	US 1998-100666P	P	19980916		
	WO 1999-US21346	W	19990916		
OS	MARPAT 132:222538				
GI					



II


AB R1COC(:ZOMe)Z1Z2Z3R [I; R = (un)substituted di- or triazolyl, -oxazolyl, -thiazolyl, etc.; R1 = OMe or NHMe; Z = CH or N; Z1 = (un)substituted 1,2-phenylene; Z2 = O, SOO-2, CH2, CH2O, CH:CH, etc.; Z3 = (un)substituted pyridinediyl] were prepared. Thus, 5,6-dichloro-3-pyridinecarbonitrile was condensed with H2NOH and the product cyclocondensed with Me3CCOCl to give, in 2 addnl. steps, 5-tert-butyl-3-(5-chloro-6-methylsulfonyl-3-pyridinyl)-1,2,4-oxadiazole which was etherified by 2-hydroxymethyl- α -methoxyimino-N-methylbenzeneacetamide to give title compound II. Data for biol. activity of I were given.

IT 261625-23-4P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-[(oxadiazolylpyridinyl)oxymethyl]- α -methoxyiminophenylacetamides as agrochem. fungicides)

RN 261625-23-4 CAPLUS

CN Benzeneacetamide, α -(methoxyimino)-N-methyl-2-[[[6-(5-phenyl-1,2,4-oxadiazol-3-yl)-2-pyridinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:253079 CAPLUS

DN 128:294783

TI New oxadiazoles, method for their preparation, and their use as drugs

IN Brenner, Michael; Maier, Roland; Wienrich, Marion; Weiser, Thomas; Palluk, Rainer; Bechtel, Wolf-Dietrich; Sagrada, Angelo; Ensinger, Helmut; Pschorn, Uwe; Cesana, Raffaele

PA Boehringer Ingelheim K.-G., Germany

SO Ger. Offen., 58 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19643037	A1	19980423	DE 1996-19643037	19961018 <--
ZA 9709220	A	19980420	ZA 1997-9220	19971015 <--
CA 2268954	AA	19980430	CA 1997-2268954	19971015 <--
WO 9817652	A1	19980430	WO 1997-EP5693	19971015 <--
W: AU, BG, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9748676	A1	19980515	AU 1997-48676	19971015 <--
AU 737552	B2	20010823		
EP 934288	A1	19990811	EP 1997-911227	19971015 <--
EP 934288	B1	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1233245	A	19991027	CN 1997-198866	19971015 <--

CN 1086698	B	20020626		
BR 9714354	A	20000411	BR 1997-14354	19971015 <--
JP 2000505089	T2	20000425	JP 1998-505639	19971015 <--
JP 3333523	B2	20021015		
RU 2182905	C2	20020527	RU 1999-111781	19971015
TW 413678	B	20001201	TW 1997-86115386	19971018 <--
NO 9901815	A	19990416	NO 1999-1815	19990416 <--
NO 312512	B1	20020521		
KR 2000049253	A	20000725	KR 1999-703360	19990416 <--
US 6277872	B1	20010821	US 1999-284382	19990726
HK 1020956	A1	20021004	HK 1999-106174	19991229
PRAI DE 1996-19643037	A	19961018		
WO 1997-EP5693	W	19971015		
OS MARPAT 128:294783				
GI				




AB The title compds. [I; R¹ = H, (un)substituted C₁-10 alkyl, C₂-10 alkenyl, C₂-10 alkynyl or Ph; X, Y = O, N; X = Y ≠ N ≠ O; Z = substituted Ph] were prepared. For example, cyclocondensation of Ph(:NH)NHOH (preparation from PhCN and NH₂OH given) with 2-HOC₆H₄CO₂Me in EtOH in the presence of NaOEt gave 92% 5-(2-hydroxyphenyl)-3-phenyl-1,2,4-oxadiazole which was etherified with Me₂NCH₂CH₂Cl in dioxane in the presence of NaH to give 64% title compound II. This at 100 μM in vitro gave 86% inhibition of kainate-induced signal at AMPA receptors.

IT **206260-77-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(new oxadiazoles, method for their preparation, and their use as neuroprotective drugs)

RN 206260-77-7 CAPLUS



CN Ethanamine, N,N-dimethyl-2-[2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:218623 CAPLUS
 DN 126:212048
 TI Substituted aromatic compounds and their pharmaceutical use as inhibitors of TNF and PDE IV.
 IN Aldous, David John; Smith, Graham Frank; Astles, Peter Charles; Pickett, Stephen Dennis; McLay, Iain McFarlane; Stuttle, Keith Alfred James; Ratcliffe, Andrew James; et al.
 PA Rhone-Poulenc Rorer Limited, UK
 SO PCT Int. Appl., 159 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9703967	A1	19970206	WO 1996-GB1746	19960722 <--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
	AU 9665268	A1	19970218	AU 1996-65268	19960722 <--
PRAI	GB 1995-15058	A	19950722		
	GB 1995-15729	A	19950801		
	GB 1996-4531	A	19960302		
	US 1996-14212P	P	19960327		
	WO 1996-GB1746	W	19960722		
OS	MARPAT 126:212048				
GI					



AB The invention describes compds. I [wherein R1 = (un)substituted alkyl, or when Z1 = bond, R1 may also = H; R2 = (un)substituted aryl, partially saturated bicycloaryl, heteroaryl, or RaRbN; R3 = (un)substituted aryl or heteroaryl; A1 = bond, (un)substituted C1-6 alkylene or C2-6 alk(en/yn)ylene optionally interrupted by O, S, phenylene, imino, alkylimino, SO, or SO2; Z1, Z2 = O, S or bond; Z3 = C.tplbond.C, CH2CZ, CZCH2, CZCZ, CH2NH, CH2O, CH2S, CH2SO, CH2SO2, CF2O, CZNH, NHCH2, OCH2, SCH2, SOCH2, SO2CH2, OCF2, OCH, NHCZ, N:N, NHSO2, SO2NH, CZCZNH, NHCOO, OCONH, C(:NORc)CH2, C(F):N, CH(F)CH2, or NHCONH; Z = O or S; Ra, Rb = alkyl or arylalkyl; or NRaRb = 4- to 6-membered cyclic amine optionally containing addnl. O, S, NH, or NRc or substituted with oxo; Rc = alkyl or arylalkyl; Q1, Q2, Q3 = CH, CX1, or N; and X1 = halo] and their N-oxides, prodrugs, pharmaceutically acceptable salts, and solvates (e.g. hydrates). The invention also describes processes for preparing I, pharmaceutical compns. comprising I, and their use in therapy as inhibitors of TNF and type IV cAMP phosphodiesterase (PDE) (no data). For example, 5-[[[(3,5-dichloropyridin-4-yl)imino]fluoromethyl]-2-methoxyphenol (preparation given) was etherified with 3-(4-chlorophenyl)-5-(hydroxymethyl)-1,2,4-oxadiazole using the Mitsunobu reaction, followed by conversion of the imidoyl fluoride function to an amide using KOSiMe3, and N-oxidation using m-ClC6H4C(O)OOH, to give title compound II.

IT **187970-09-8P 187970-75-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of substituted aromatic compds. as inhibitors of

TNF

and PDE IV)


RN 187970-09-8 CAPLUS

CN Benzoic acid, 4-methoxy-3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 187970-75-8 CAPLUS

CN Benzoic acid, 4-methoxy-3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI)
(CA INDEX NAME)



IT 187969-18-2P 187969-57-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted aromatic compds. as inhibitors of TNF and PDE

IV)


RN 187969-18-2 CAPLUS

CN Benzamide, N-(3,5-dichloro-4-pyridinyl)-4-methoxy-3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



RN 187969-57-9 CAPLUS

CN Benzamide, N-(3,5-dichloro-4-pyridinyl)-4-methoxy-3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



L10 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:743723 CAPLUS

DN 126:18874

TI Preparation of benzimidazoles as modulators of the GABAA receptor complex
IN Teuber, Lene; Waetjen, Frank; Fukuda, Yoshimasa; Ushiroda, Osamu; Sasaki, Toshiro

PA Neurosearch A/S, Den.; Meiji Seika Kaisha, Ltd.

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9633194	A1	19961024	WO 1996-EP1606	19960417 <--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	CA 2218493	AA	19961024	CA 1996-2218493	19960417 <--
	CA 2218493	C	20050222		
	AU 9656891	A1	19961107	AU 1996-56891	19960417 <--
	AU 695957	B2	19980827		
	EP 821684	A1	19980204	EP 1996-914932	19960417 <--
	EP 821684	B1	20011205		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI				
	CN 1182427	A	19980520	CN 1996-193419	19960417 <--
	CN 1072669	B	20011010		
	JP 11501320	T2	19990202	JP 1996-531464	19960417 <--
	JP 3342874	B2	20021111		
	RU 2135493	C1	19990827	RU 1997-119173	19960417 <--
	BR 9608048	A	19991130	BR 1996-8048	19960417 <--
	CZ 287545	B6	20001213	CZ 1997-3292	19960417 <--
	AT 210132	E	20011215	AT 1996-914932	19960417
	EP 1164134	A1	20011219	EP 2001-112476	19960417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	SK 282425	B6	20020107	SK 1997-1399	19960417
	PL 183853	B1	20020731	PL 1996-322892	19960417
	EE 4310	B1	20040615	EE 1997-283	19960417
	CA 2217601	AA	19961024	CA 1996-2217601	19960419 <--
	CA 2217601	C	20020416		
	CN 1182426	A	19980520	CN 1996-193420	19960419 <--
	NO 9704844	A	19971216	NO 1997-4844	19971020 <--
	NO 314504	B1	20030331		

US 5922724	A	19990713	US 1998-945023	19980205 <--
HK 1015674	A1	20021011	HK 1998-111156	19981009
PRAI DK 1995-460	A	19950421		
EP 1996-914932	A3	19960417		
WO 1996-EP1606	W	19960417		
OS MARPAT 126:18874				
GI				



I



II


AB The title compds. [I; R1, R2 = H, (un)substituted furanyl, isoxazolyl; R3 = II (wherein A, B, D = each CH, or one or two of A, B and D = N and the others are CH; R4 = (un)substituted Ph, benzimidazolyl, or monocyclic heteroaryl)], useful for the treatment of various CNS disorders such as epilepsy and other convulsive disorders, anxiety, sleep disorders and memory disorders, were prepared. Thus, cyclization of N-[3-(1-imidazolyl)phenyl]-2-amino-4-(3-furanyl)aniline with HCOOH afforded 84% I [R1 = 3-furanyl; R2 = H; A, B, D = CH; R4 = 1-imidazolyl] which showed IC50 of 0.4 nM against the specific binding of 3H-FNM.

IT **184097-27-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazoles as modulators of the GABAA receptor complex)

RN 184097-27-6 CAPLUS

CN 1H-Benzimidazole, 5-(3-furanyl)-1-[3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:580566 CAPLUS

DN 125:300997

TI Benzimidazole compounds useful as benzodiazepine receptor ligands

IN Teuber, Lene; Axelsson, Oskar; Watjen, Frank

PA Neurosearch A/s, Den.; Meiji Seika Kaisha, Ltd.

SO U.S., 19 pp., Cont.-in-part of U.S. Ser. No. 207,774, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

PATENT NO.


KIND

DATE

APPLICATION NO.

DATE

PI	US 5554630	A	19960910	US 1995-410572	19950324 <--
	ZA 9402079	A	19941024	ZA 1994-2079	19940324 <--
	US 5554632	A	19960910	US 1994-352585	19941209 <--
PRAI	DK 1993-337	A	19930324		
	DK 1993-1055	A	19930921		
	US 1994-207774	B2	19940308		
OS	MARPAT 125:300997				
GI					




AB The invention discloses title compds. I [R³ = certain (un)substituted (hetero)aryl groups; R⁴ = H, NH₂, NO₂, cyano, halo, acylamino, (un)substituted aryl; or R⁴ forms bridges to aryl ring of R³; R⁶, R⁷ = H, halo, NH₂, NO₂, cyano, acylamino, CF₃, (un)substituted aryl; or R⁶ and R⁷ form certain optionally heteroatom-containing bridges] and their pharmaceutically acceptable salts, as well as the medical use of a broader class of 1-arylbenzimidazoles, including I. The compds. are useful for the treatment of various central nervous system disorders such as epilepsy and other convulsive disorders, anxiety, sleep disorders, and memory disorders. For example, 2-amino-3'-iodo-4-(trifluoromethyl)diphenylamine (preparation given) underwent cyclocondensation with formic acid at reflux, and coupling with imidazole in the presence of K₂CO₃ and CuBr at 200°, to give title compound II [R⁶ = CF₃]. In an in-vivo test for inhibition of [3H]-flunitrazepam specific binding to mouse forebrain GABA_A receptors, II [R⁶ = CF₃] had an ED₅₀ of 7.3 mg/kg i.p., and II [R⁶ = Me] had an ED₅₀ of 0.8 mg/kg i.p.

IT **182630-95-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazole derivs. as benzodiazepine receptor ligands)


RN 182630-95-1 CAPLUS

CN 1H-Benzimidazole, 5-(1,1-dimethylethyl)-1-[3-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1995:570765 CAPLUS
 DN 122:314571
 TI Preparation of substituted heterocycle compounds enhancing antitumor activity of other cytotoxic agents
 IN Arnold, Lee D.; Coe, Jotham W.; Kaneko, Takushi; Moyer, Mikel P.
 PA Pfizer Inc., USA
 SO PCT Int. Appl., 157 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9422846	A1	19941013	WO 1994-US1724	19940228 <--
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FI 9401452	A	19941001	FI 1994-1452	19940329 <--
PRAI	US 1993-40233	A	19930330		
OS	MARPAT 122:314571				
GI					




I

AB Title compds. R100R101R102N (R100 = Q1A1B1Y2(CH2)mCH(Z1)Y1, Q1O(CH2)2C(OH)(R103)CH2, substituted cycloalkyl, etc., wherein R103 = C1-4 alkyl, Y1 = O, H2C, (CH2)2, bond; Z1 = H, HO, F3C, O2N, C1-4 alkoxy; Y2 = O, S, HN, MeN, bond, CONH, NHCO; B1 = bond, substituted Ph; A1 = bond, C1-4 alkylene, O, S, HN; Q1 = (substituted) heterocyclyl, (substituted) aryl; R100, R101 = H, C1-4 alkyl, C2-4 alkenyl-Ph, C1-4 alkyl-substituted Ph; R102 = H, (substituted)aryl, (substituted)heterocyclyl, etc.) and a salt thereof, useful for inhibiting P-glycoprotein in a mammal and as anticancer agents (no data), are prepared 2-Methyl-7-(2-oxiranylmethoxy)benzothiazole and 1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazine were refluxed to give the title compound I.


IT **163296-44-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted heterocycle compds. enhancing antitumor activity of other cytotoxic agents)


RN 163296-44-4 CAPLUS
 CN Piperazine, 1-(diphenylmethyl)-4-[3-[2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenoxy]propyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1985:487815 CAPLUS
 DN 103:87815
 TI Antiparasitic agents. 6. Synthesis and anthelmintic activities of novel isothiocyanatophenyl-1,2,4-oxadiazoles
 AU Haugwitz, R. D.; Martinez, A. J.; Venslavsky, J.; Angel, R. G.; Maurer, B. V.; Jacobs, G. A.; Narayanan, V. L.; Cruthers, L. R.; Szanto, J.
 CS Squibb Inst. Med. Res., Princeton, NJ, 08540, USA
 SO Journal of Medicinal Chemistry (1985), 28(9), 1234-41
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 OS CASREACT 103:87815
 GI



I




II

AB The synthesis and anthelmintic activities of 31 3- and 5-(isothiocyanatophenyl)-1,2,4-oxadiazoles were given. In the primary anthelmintic screen, 3-(4-isothiocyanatophenyl)-1,2,4-oxadiazole (I) showed 100% nematocidal activity and 3-(2-furanyl)-5-(4-isothiocyanatophenyl)-1,2,4-oxadiazole (II), 3-(2-furanyl)-5-(2-chloro-4-isothiocyanatophenyl)-1,2,4-oxadiazole, and 3-(2-furanyl)-5-(4-chloro-3-isothiocyanatophenyl)-1,2,4-oxadiazole showed 100% taeniocidal activity when administered orally to mice. The two most active members of this series, I and II were active against gastrointestinal nematodes of sheep at 100 mg/kg. I was also active against hookworms in dogs at a single oral dose of 200 mg/kg.

IT **96898-70-3P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and nematocidal activity of)

RN 96898-70-3 CAPLUS

CN Pyridine, 2-[5-(4-isothiocyanatophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




IT 96898-94-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with thiophosgene)

RN 96898-94-1 CAPLUS

CN Benzenamine, 4-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



L10 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1981:550674 CAPLUS

DN 95:150674

TI 1,2,4-Oxadiazole derivatives

PA Sumitomo Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 12 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56065881	A2	19810603	JP 1979-142540	19791101 <--
PRAI	JP 1979-142540	A	19791101		
GI					



I

AB Thirty-one 1,2,4-oxadiazole derivs. I (R = H, alkyl, alkenyl, etc.; R1 = H, halo, NO2, OH, etc.; R2 = H, alkyl; R3 = OH, alkoxy, hydroxyalkoxy, etc.) were prepared by, e.g., reaction of RCO2H derivs. with R3COCHR2C6H3R1C(:NOH)NH2 followed by intramol. cyclodehydration of the


resulting R3COCHR2C6H3R1C(NH2):NO2CR. I had antiinflammatory, analgesic, and antipyretic activities (no data). Thus, 0.51 g AcCl reacted with 1.4 g 4-EtO2CCHMeC6H4C(:NOH)NH2 in THF containing Et3N to give 1.65 g 4-EtO2CCHMeC6H4C(NH2):NOAc, which was refluxed in PhMe 10 h to give 1.2 g 3-[4-[α -(ethoxycarbonyl)ethyl]phenyl]-5-methyl-1,2,4-oxadiazole.

IT **79148-35-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 79148-35-9 CAPLUS

CN Benzeneacetic acid, α -methyl-4-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)



L10 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1980:130618 CAPLUS

DN 92:130618

TI Stilbene compounds

IN Erckel, Ruediger; Roesch, Guenther

PA Hoechst A.-G., Fed. Rep. Ger.

SO Ger. Offen., 15 pp. Addn. to Ger. Offen. 2,709,924.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2820322	A1	19791115	DE 1978-2820322	19780510 <--
	ES 480216	A1	19791016	ES 1979-480216	19790504 <--
	EP 7392	A1	19800206	EP 1979-101404	19790508 <--
	EP 7392	B1	19830608		
	R: AT, BE, CH, DE, FR, GB, IT, NL, SE				
	AT 3715	E	19830615	AT 1979-101404	19790508 <--
	DK 7901915	A	19791111	DK 1979-1915	19790509 <--
	AU 7946883	A1	19791115	AU 1979-46883	19790509 <--
	AU 521927	B2	19820506		
	BR 7902845	A	19791127	BR 1979-2845	19790509 <--
	JP 54151977	A2	19791129	JP 1979-55810	19790509 <--
	ZA 7902227	A	19800528	ZA 1979-2227	19790509 <--
	CA 1111036	A1	19811020	CA 1979-327257	19790509 <--
	US 4310665	A	19820112	US 1980-191000	19800926 <--
PRAI	DE 1978-2820322	A	19780510		
	US 1979-36688	A1	19790507		
	EP 1979-101404	A	19790508		

GI



I


AB Stilbene derivs. (I; R, R1 = H, F, Cl, Ph, lower alkyl, lower alkoxy, lower dialkylamino, lower trialkylammonium, acylamino, CO₂H or SO₃H derivs.; R1 = phenylene, lower alkylene, 1,3-dioxapropylene; R2 = heterocycl-1,2,4-oxadiazolyl) with fluorescence maximum 428-483 nm (DMF) are prepared for use as whiteners for plastics and synthetic fibers. Thus, 4'-benzoxazol-2-ylstilbene-4-carbonyl chloride [4763-80-8] was added to pyridine-4-amidoxime [1594-57-6] in DMF, the reaction mixture heated, refluxed, and filtered to give I (R = R1 = H, R2 = 3-(4-pyridyl)-1,2,4-oxadiazol-5-yl) [73097-43-5] with fluorescence maximum (DMF) 432 nm.

IT **73097-38-8P 73097-39-9P**

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and fluorescence of)


RN 73097-38-8 CAPLUS

CN Benzoxazole, 2-[4-[2-[4-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]ethenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 73097-39-9 CAPLUS

CN Benzoxazole, 5-methyl-2-[4-[2-[4-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]ethenyl]phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1971:40840 CAPLUS

DN 74:40840

TI Relation between chemical structure and pharmacological activity in a series of central muscle relaxant oxadiazole derivatives

AU Leszkovsky, Gyorgy; Tardos, Laszlo

CS Pharmacol. Res. Lab., Chinoin Pharm. Chem. Works, Budapest, Hung.

SO Acta Physiologica Academiae Scientiarum Hungaricae (1970),
37(3-4), 319-26
CODEN: APACAB; ISSN: 0001-6756

DT Journal

LA English


GI For diagram(s), see printed CA Issue.

AB 3-(4-Pyridyl)-5-(2-chlorophenyl)-1,2,4-oxadiazole (I) and 34 derivs. were compared for their ability to inhibit strychnine and electroshock convulsions and nicotine toxicity in mice. Only 3-(2-pyridyl)-5-(2-chlorophenyl)-1,2,4-oxadiazole was generally as active as I. 3-(α -Aminobenzyl)-5-(2-chlorophenyl)-1,2,4-oxadiazole inhibited not only nicotine toxicity but also pentetrazole convulsions, which I did not do. Activity of I was reduced, but not completely abolished, by reversing the position of the substituents. Quarternization of the pyridine ring also abolished effectiveness. The Cl atom attached to the N through a C chain containing 3 C atoms in sp² hybrid state seemed of crucial importance for pharmacol. activity. A further factor necessary for pharmacol. activity seems to be the attachment to the other C atom of the oxadiazole ring of an aromatic group (4-pyridyl or 2-pyridyl) having a N atom and an appropriate electron distribution.

IT **27199-42-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antispasmodic activity of)

RN 27199-42-4 CAPLUS

CN Pyridine, 2-[5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



proviso out

L10 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1971:13156 CAPLUS

DN 74:13156

TI Therapeutic pyridyl-1,2,4-oxadiazoles

IN Harsanyi, Kalman; Reiter, Jozsef; Korbonits, Dezso; Takacs, Kalman; Bako, Erzsebet; Leszkovszky, Gyorgy; Tardos, Laszlo; Vertesy, Csaba

PA Chinoin Gyogyszer- es Vegyeszeti Termekek Gyara Rt.

SO Ger. Offen., 20 pp.
CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1920037	A	19701112	DE 1969-1920037	19690419 <--
	US 3647809	A	19720307	US 1969-815520	19690408 <--
	IL 31990	A1	19740516	IL 1969-31990	19690408 <--
	GB 1271302	A	19720419	GB 1969-1271302	19690414 <--
	AT 292727	B	19710910	AT 1969-3754	19690418 <--
	AT 292728	B	19710910	AT 1970-8156	19690418 <--

FR 2007529	A5	19700113	FR 1969-12994	19690424 <--
FR 2007529	B1	19730316		
CH 540925	A	19731015	CH 1969-6275	19690424 <--
CH 542232	A	19731115	CH 1972-14769	19690424 <--
BE 732131	A	19691001	BE 1969-732131	19690425 <--
NL 6906401	A	19691028	NL 1969-6401	19690425 <--
NO 124253	B	19720327	NO 1969-1733	19690425 <--
BR 6908381	A0	19730208	BR 1969-208381	19690425 <--
JP 48024394	B4	19730720	JP 1969-32259	19690425 <--
SE 368576	B	19740708	SE 1969-5909	19690425 <--
CA 954858	A1	19740917	CA 1969-49755	19690425 <--
PL 79435	P	19750630	PL 1969-133199	19690425 <--
PRAI HU 1968-CI796	A	19680426		
GI	For diagram(s), see printed CA Issue.			
AB	The antitussive, spasmolytic, local anesthetic, and coronary dilating title compds. (I) were prepared Thus, refluxing II and 0-ClC ₆ H ₄ CO ₂ Et in EtOH 8 hr gave 81.5% I (R = 2-pyridyl, R ₁ = 0-ClC ₆ H ₄). Among 31 compds. similarly prepared were I (R and R ₁ given): 4-pyridyl, p-ClC ₆ H ₄ ; o-EtOC ₆ H ₄ , 3-pyridyl; styryl, 4-pyridyl; 3-pyridyl, o-ClC ₆ H ₄ ; 4-pyridyl, 4-pyridyl; 4-pyridyl, 3-pyridyl.			
IT	27199-42-4P			
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)			
RN	27199-42-4 CAPLUS			
CN	Pyridine, 2-[5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)			



L10 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1970:100719 CAPLUS

DN 72:100719

TI Pyridyloxadiazole derivatives

IN Harsanyi, Kalman; Reiter, Jozsef; Korbonits, Dezso; Gonczi, Csaba; Takacs, Kalman; Bako, Erzsebet; Leszkovszky, Gyorgy; Tardos, Laszlo; Vertessy, Csaba

PA Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt

SO Hung., 24 pp.

CODEN: HUXXAT

DT Patent

LA Hungarian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	HU 156976		19700131	HU	19680426 <--
	FR 2007529			FR	

GI For diagram(s), see printed CA Issue.

AB A mixture of 0.1 mole iso-nicotinamide oxime (I) and 0.2 mole o-ClC₆H₄CO₂Et in 60 ml absolute EtOH was refluxed 30 min, 0.1 mole NaOEt in 40 ml absolute EtOH


added, and the mixture refluxed 8 hr to give 83% II (R = 4-pyridyl, R1 = o-ClC6H4) (IIa) m. 111° (96% EtOH); methiodide m. 247° (80% EtOH). IIa was also obtained by treating I with o-ClC6H4COCl-pyridine, (o-ClC6H4CO)2O-C6H6, by heating I with o-ClC6H4CHO or o-ClC6H4CH(OMe)2, and with o-ClC6H4-COCl in alkaline medium, followed by heating the isonicotinamide oxime o-chlorobenzoate 1 hr at 130°. Similarly prepared were II (R, R1, and m.p. given): 2-pyridyl, o-ClC6H4, 93-5° (EtOH); o-ClC6H4, 4-pyridyl, 138-40° (EtOH) methiodide m. 231-2° (80% EtOH); 4-pyridyl, p-ClC6H4, 168-70°; o-EtOC6H4, 3-pyridyl, 121-2°; PhCH:CH, 4-pyridyl, 115°; 3-pyridyl, o-ClC6H4, 85°; 3-pyridyl, p-H2NC6H4, 217°; 3-pyridyl, piperidinomethyl, -(maleate m. 141°); 3-pyridyl, 2-(1-pyrrolidinyl)-ethyl, -(maleate m. 135°); 2-pyridyl, 2-piperidinoethyl, -(maleate m. 135°); 2-pyridyl, 2-morpholinoethyl, -(di-HCl salt m. 198°); 3-pyridyl, p-ClC6H4OCH2, 135-8°; 4-pyridyl, Me, 97°; 4-pyridyl, 3-pyridyl, 134°; 4-pyridyl, 4-pyridyl, 164°; 4-pyridyl, 2-piperidinoethyl, 149°; 4-pyridyl, 2-morpholinoethyl, 143°; 2-ethyl-4-pyridyl, Me, -(HCl salt m. 221°); 2-ethyl-4-pyridyl, o-ClC6H4, 66°; 2-ethyl-4-pyridyl, 2-pyridyl, -(di-HCl salt m. 230°); 2-ethyl-4-pyridyl, o-HOC6H4, 103°; 2-ethyl-4-pyridyl, 4-pyridyl, 67°; 2-ethyl-4-pyridyl, 2-ethyl-j-pyridyl, -(di-HCl salt m. 253°); 2-ethyl-4-pyridyl, p-ClC6H4-CH2, -(HCl salt m. 185-7°); 4-pyridyl, p-ClC6H4OCH2, 146-7°; 2-ethyl-4-pyridyl, 2-piperidinoethyl, -(di-HCl salt m. 218°).

IT 27199-42-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 27199-42-4 CAPLUS

CN Pyridine, 2-[5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



L10 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1967:464308 CAPLUS

DN 67:64308

TI The conversion of imidazo[1,5-a]pyridines into 3-(2-pyridyl)-1,2,4-oxadiazoles

AU Paudler, William W.; Kuder, James E.

CS Ohio Univ., Athens, OH, USA

SO Journal of Organic Chemistry (1967), 32(8), 2430-3

CODEN: JOCEAH; ISSN: 0022-3263

DT Journal

LA English

GI For diagram(s), see printed CA Issue.

AB Imidazo[1,5-a]pyridine (I) and its 3-Me and 3-Ph derivs. rearrange, upon treatment with HONO, to 3-(2-pyridyl)-1,2,4-oxadiazole (II) and its 5-Me (III) and 5-Ph (IV) derivs., resp. Pyrolysis, alkaline hydrolysis, as well as mass, uv, and N.M.R. spectral studies were used to establish the


structures of the rearrangement products. Compounds II and III were prepared by unequivocal syntheses. 19 references.

IT 13389-61-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 13389-61-2 CAPLUS

CN Pyridine, 2-(5-phenyl-1,2,4-oxadiazol-3-yl)- (8CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

133.67

470.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-24.00

-24.00

STN INTERNATIONAL LOGOFF AT 12:39:33 ON 24 JAN 2006

10/699.563

File Copy

